BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open’s open peer review process please email info.bmjopen@bmj.com

---

**Note from the Editor:** Please note that there has been a minor change in the published article relating to the use of the Morisky scale to measure adherence. The authors explain this change in a linked response to the article (http://bmjopen.bmj.com/content/7/12/e018302.responses), which we have reproduced here:

**Response to query regarding use of the Morisky scale**

Xiqian Huo, Cardiologist, China Oxford Center for International Health Research, Fuwai Hospital, National Center for Cardiovascular Diseases

**Other Contributors:**

Erica S. Spatz

April 13, 2018

During the study design period, we planned to use a Chinese version of the Morisky scale to assess medication adherence. This version was previously validated and available for use in China. In 2017, we were informed by Dr. Morisky team that we need to pay to use the scale. After careful consideration, we opted not to use the Morisky scale and declined to pay the fee. These developments occurred during the submission and review process at BMJ Open. As such, the initial version of the manuscript noted the use of the Morisky scale to assess adherence, though this was deleted from the revised and published version. Instead, we will assess adherence using detailed medication information obtained during each follow-up visit.
# Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

<table>
<thead>
<tr>
<th>Journal:</th>
<th>BMJ Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bmjopen-2017-018302</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Protocol</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>20-Jun-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Huo, Xiqian; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Spatz, Erica; Yale University  
Ding, Qingle; Yale University  
Horak, Paul; Yale University  
Zheng, Xin; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Masters, Claire; Yale University  
Zhang, Haibo; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research  
Irwin, Melinda; Yale School of Public Health  
Yan, Xiaofang; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Guan, Wenchi; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research  
Li, Jing; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research  
Li, Xi; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Spertus, John; Mid America Heart Institute of Saint Luke's Hospital  
Masoudi, Frederick; Division of Cardiology, University of Colorado Anschutz Medical Campus  
Krumholz, Harlan; Yale School of Public Health  
Jiang, Lixin; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease |
| Primary Subject Heading: | Research methods |
| Secondary Subject Heading: | Research methods, Medical management |
| Keywords: | Coronary heart disease < CARDIOLOGY, diabetes, text messaging, behavioral intervention, secondary prevention |
Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

Xiqian Huo, MD*; Erica S. Spatz, MD, MHS*; Qinglan Ding, MS; Paul Horak, BS; Xin Zheng, MD, PhD; Claire Masters, MHP; Haibo Zhang, MD; Melinda Irwin, PhD, MPH; Xiaofang Yan, MD; Wenchi Guan, MD; Jing Li, MD, PhD; Xi Li, MD, PhD; John A. Spertus, MD, MPH; Frederick A. Masoudi, MD, MSPH; Harlan M. Krumholz, MD, SM**; Lixin Jiang, MD, PhD**

(* Joint first authors)
(** Joint senior authors)

China Oxford Center for International Health Research, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China (X.H, X.Z, H.Z, X.Y, W.G, J.L, X.L, L.J);

Center for Outcomes Research and Evaluation, Yale University/Yale-New Haven Hospital, New Haven, Connecticut, USA (E.S.S, Q.D, P.H, C.M, M.I, H.M.K);

Health Outcomes Research, Saint Luke’s Mid America Heart Institute/University of Missouri-Kansas City, Kansas City, Missouri, USA (J.A.S);
Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA (F.A.M).

Correspondence: Lixin Jiang, MD, PhD, National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, 167 Beilishi Road, Xicheng District, Beijing, 100037, People’s Republic of China. Tel: +86 10 8839 6203; Fax: +86 10 8836 5201. Email: jiangl@fwoxford.org

ABSTRACT

Introduction: Mobile health interventions have the potential to promote risk factor management and lifestyle modification, and are a particularly attractive approach for scaling across healthcare systems with limited resources. We are conducting two randomized trials to evaluate the efficacy of text-based health messages in improving secondary coronary heart disease (CHD) prevention among patients with or without diabetes.

Methods and analysis: The Cardiovascular Health And Text messaging (CHAT) and CHAT-Diabetes Mellitus (CHAT-DM) Studies are multi-center, single-blind, randomized controlled trials of text messaging versus standard treatment with 6 months of follow-up conducted in 37 hospitals throughout 17 provinces in China. The intervention group receives 6 text messages per week which target blood pressure control, medication adherence, physical activity, smoking cessation (when appropriate), glucose monitoring and lifestyle
recommendations including diet (in CHAT-DM). The text messages were
developed based on behavioral change techniques, using models such as
information-motivation-behavioral skills model, goal-setting and provision of
social support. The estimated sample size is 790 in CHAT Study and 480 in
CHAT-DM Study. In CHAT, the primary outcome is the change in systolic blood
pressure (SBP) at 6 months. Secondary outcomes include a change in
proportion of patients achieving a SBP<140mm Hg, low-density lipoprotein
cholesterol (LDL-C), physical activity, medication adherence, body mass index
(BMI), and smoking cessation. In CHAT-DM, the primary outcome is the
change in glycemic hemoglobin (HbA1C) at 6 months. Secondary outcomes
include a change in proportion of patients achieving HbA1C<7%, fasting blood
glucose, SBP, LDL-C, BMI, physical activity and medication adherence.

**Ethics and dissemination:** The central ethics committee at the China
National Center for Cardiovascular Disease (NCCD) approved the CHAT and
CHAT-DM studies. Results will be disseminated via usual scientific forums
including peer-reviewed publications.

**Trial registration number:** CHAT (NCT02888769) and CHAT-DM
(NCT02883842); pre-results.

**KEYWORDS:** coronary heart disease, diabetes, text messaging, behavioral
intervention, secondary prevention
Strengths and Limitations of study:

1. The main strengths of the study are that it evaluates the efficacy of an innovative, simple, scalable and cost-effective solution for improving secondary prevention of CHD. The trials are the first to investigate the effectiveness of text messages to support management of CHD and DM among a large and diverse population in China, and have the potential for scaling across healthcare systems in resource-constrained settings.

2. The study addressed the role of text messages in managing multiple risk factors in patients with CHD or DM. Moreover, there is currently little evidence about the effectiveness of such interventions for high-risk patients with coronary heart disease and diabetes.

3. The CHAT and CHAT-DM studies are further distinguished by their relative large sample sizes and culturally appropriate, theory-driven text messages. The messages were developed using behavior change technique and tailored to a specific Chinese patient population.

4. In contrast to most prior single center text-messaging trials, these two studies are conducted at 37 participating sites spread across a large and geographically diverse country, the results of which may be more generalizable.

5. However, medication adherence and physical activity are measured by self-report, which carries the possibility of recall bias and social desirability bias.
INTRODUCTION

The benefits of secondary prevention strategies for coronary heart disease (CHD) targeting lifestyle modification and risk factor management are well-established worldwide, however adoption of these strategies is suboptimal. Smoking, inactivity and obesity are prevalent among people with established CHD and control of hypertension and diabetes are often suboptimal. Additionally, medication adherence is poor. Prior studies reveal that only one quarter of hospitalized patients do not fill all prescriptions within 120 days of hospital discharge. Furthermore, less than half of patients hospitalized with acute myocardial infarction (AMI) are adherent to evidence-based medications 1 year later, with the greatest gaps in adherence occurring in the first 6 months after treatment initiation.

In lower and middle-income countries (LMICs), including China, which face a growing burden of cardiovascular disease and greater challenges to medication access for secondary prevention, over two-thirds of patients with CHD take no medication. While high medication costs are influential, there is also limited time for education and consultation regarding lifestyle and medication management during clinic visits, which tend to be very brief. Therefore, innovative and cost-effective interventions to enhance adherence are urgently needed.

The pervasiveness of mobile phones to enhance the adoption of secondary prevention strategies for CHD in LMICs provides a promising opportunity. Mobile phones already serve as a primary, inexpensive and quick form of communication, alerts and reminders. In addition, the number of mobile phone
users has grown exponentially in the past decade worldwide, and is projected to reach 4.77 billion by 2017,\textsuperscript{14} with nearly 200,000 messages sent every second.\textsuperscript{15} As of August 2016, China had the largest number of mobile phone owners in the world, at 1.3 billion.\textsuperscript{16} Mobile phones are also used across all geographic regions and income levels. Due to its ubiquity and convenience, mobile phone text messaging has the potential to be a scalable and powerful tool to deliver health information.\textsuperscript{17, 18}

Prior studies of mobile phone text messaging have been conducted to improve glycemic control,\textsuperscript{19} hypertension,\textsuperscript{20} medication adherence,\textsuperscript{21} as well as to promote smoking cessation,\textsuperscript{22} and physical activity.\textsuperscript{23} These trials have contributed important knowledge, and some, such as TEXT-ME\textsuperscript{24} and TExT-MED\textsuperscript{25} suggest that text-messaging interventions can influence patient behaviors and improve risk profiles. Still, several questions remain about the generalizability of these findings, especially for populations from LMICs. Most trials to date have been designed to target a single condition; yet patients with cardiovascular disease usually manage multiple conditions, requiring several lifestyle and treatment recommendations. Additionally, most studies of text messaging interventions have not been grounded in behavioral change techniques (BCT),\textsuperscript{26, 27} which may influence the efficacy and generalizability of the intervention. Finally, most prior studies have been limited to single site interventions, many of which were underpowered and/or limited by selection bias. More data are needed to understand whether text-messaging interventions should be adopted as an effective strategy for supporting cardiovascular disease prevention among diverse populations from LMICs.
Accordingly, we designed and conducted the Cardiovascular Health And Texting (CHAT) and CHAT-Diabetes Mellitus (CHAT-DM) studies. The primary objective of these two studies is to evaluate the efficacy of an automated text message-based intervention, based on behavioral change techniques, in improving risk factor control and adoption of healthy lifestyle behaviors among patients with known CHD, with or without DM, who were discharged from multiple hospitals throughout China.

METHODS AND ANALYSIS

Study Overview

The CHAT and CHAT-DM studies are multi-center, single-blind, 2-arm, randomized controlled trials of an automated mobile phone text message-based intervention with 6 months of follow-up. Patients were recruited from 37 hospitals across 17 provinces in China (Figure 1). The enrollment of participants began on August 16, 2016. The two studies were registered at http://www.clinicaltrials.gov (NCT02888769 and NCT02883842) accordingly. All participants provided written informed consent at the initial trial visit.

Study Population

In CHAT, patients were eligible if they had established CHD defined as having a history of AMI and/or percutaneous coronary intervention (PCI), having access to a mobile phone to read and send text messages, and did not have
diabetes. In CHAT-DM, patients were eligible if they had a history of documented CHD (as defined in CHAT) and diabetes, and had access to a mobile phone to read and send text messages. In both studies, patients were excluded if they could not read or send text messages, had cognitive or communication disorders, or could not provide informed consent. A ‘screening log’ of basic demographic information and reasons for not participating in patients deemed ineligible but who declined to participate has been maintained.

Randomization and blinding

Participants were randomly allocated to either the intervention or control arms in a 1:1 ratio using a computerized randomization system. In order to achieve a balance of participants’ characteristics in both arms, we employed a stratified randomization approach, based on age, gender, AMI history, education degree and medical insurance type within each study. Researchers, statisticians and clinic staff were blinded to treatment allocation.

Trial intervention

Participants in the intervention groups of the CHAT and CHAT-DM studies receive semi-personalized text messages about CHD risk factor modification for 6 months as well as standard treatment (described below). The control group in both studies receive two thank-you text messages that contain no medical information each month as well as standard treatment. A training
session was held by research staff upon enrollment to ensure that all
participants were capable of receiving, reading and sending text messages on
their mobile phones. Participants were also instructed how to withdraw from
the study should they desire, by responding with a specific character.
Researchers could monitor the status of text message delivery, review
responses sent by participants and manage withdrawal via a customized
software platform. For instance, logs were kept to assess the proportion of text
messages successfully delivered, the exact time of messages being sent and
the reasons for those that failed to be sent.

CHAT and CHAT-DM intervention development

A bank of 550 text messages (280 in CHAT and 270 in CHAT-DM) was
developed by a multidisciplinary team of cardiologists, endocrinologists,
psychologists, nurses and public health researchers using a three-phase
systematic and iterative approach (Figure 2). In CHAT study, text messages
are categorized into five groups: (1) general education on CHD and AMI, (2)
medication adherence, (3) blood pressure control, (4) physical activity, and (5)
smoking cessation. The text messages in CHAT-DM study cover a range of
diabetes self-management topics including: (1) general education on CHD and
DM, (2) medication adherence, (3) glucose monitoring and control, (4) blood
pressure control, (5) physical activity, and (6) lifestyle recommendations such
as diet and foot care. All text messages are in Chinese, and each text
message is less than 70 Chinese characters, which would be equivalent to
about 140-160 character message in English.
Phase 1 Approach to developing text messages

Text messages were originally drafted by members of the research team in Chinese based on current guidelines and standards of care pertaining to cardiovascular health and diabetes care. All messages were grounded in behavioral change techniques previously used to develop short health messages, providing information, goal-setting, motivation, social support and stress management advice. Efforts were devoted to selecting the behavioral change techniques most applicable to the Chinese cultural context and compatible with Chinese beliefs and values (Table 1). For example, some text messages applied traditional Chinese aphorisms, chengyu, and catchy rhyme schemes in order to make them more acceptable to patients. As another example, in designing text messages that were motivating, especially in challenging situations, the multidisciplinary group felt that Chinese people tend to prefer more direct and structured counseling instructions rather than indirect and insight-oriented approaches (a category of psychotherapeutic approaches that promote individuals’ adaptive behavior and course of action in life through understanding their internal motivation); as such, text messages were written to provide practical approaches and real-life examples instead of abstract theories. Social and family-oriented goals were used more often than individual achievement to help improve health behaviors, consistent with cultural norms in China. These messages were sent to experts in behavioral change techniques and counseling for review and were used as examples to draft the initial bank of 550 text messages. Once drafted, all messages were reviewed, critiqued and revised within the internal research team.
Phase 2 Expert review

An expert panel made up of clinicians and academics reviewed each round of text message drafts with a different focus in each iteration. First, clinical experts (cardiologists, endocrinologists and psychologists) considered the accuracy, clarity and clinical benefit of each text message. Second, 21 messages from all categories in the CHAT and CHAT-DM studies text banks were randomly selected and translated into English by bilingual researchers. Experts in the fields of cardiology, endocrinology, epidemiology, psychology and behavioral science in the U.S. reviewed them and provided suggestions for further refinement. Finally, Chinese researchers and a linguist reviewed all 550 text messages, further refined the language, and paid special attention to the cultural meaning of all text messages to ensure better understanding among the targeted population (elderly Chinese patients with cardiovascular disease, with and without diabetes). Once feedback from the experts was addressed, the text bank was updated and prepared for user testing.

Phase 3 User testing and pilot study

For user testing, 19 randomly selected text messages from the finalized text bank in the CHAT and CHAT-DM studies were distributed to 39 individuals with CHD (with or without diabetes) for feedback. Likert-type items in a survey were used to assess usefulness and ease of understanding of the text messages. Open-ended questions were asked to obtain suggestions for improvement from participants. In total, 92.4% (582/630) rated the messages as easy to understand and 93.2% (587/630) rated the messages as useful. All 550 text messages were further modified based on feedback from user testing.
Results of the scores for the message categories in this phase are summarized in Table 2.

Next, the refined text message banks underwent pilot testing to evaluate the efficacy of the message delivery system and quality of the user experience. A customized software program sent messages through a gateway interface, allowing them to be sent to all individuals’ mobile phones free of charge and at a bulk-rate cost (0.1 yuan per message, or .01 USD) to the research team. Participants from the user testing were enrolled in the pilot testing after providing written informed consent (n=33). For the pilot study, messages drawn from the entire text bank were sent to participants. At the end of the 1-month pilot study, 30 participants reported their experience of receiving messages and commented on frequency, timing, content and potential impact of text messages. Minor changes were made to the text message bank following the pilot study based on this feedback.

**Frequency and timing of text message delivery**

Each participant in the intervention group of the CHAT and CHAT-DM studies receives 6 text messages per week, randomly selected by the software system, across a 6 month timeframe. The messages are sent at one of three random times (9am, 12pm or 4pm), during weekends and weekdays (excluding Monday to give people a break). In the CHAT study, participants receive two general education messages on CHD (one if an active smoker), two blood pressure control messages, one medication adherence message, and one physical activity message per week. Smokers receive one smoking cessation message per week. Participants in the CHAT-DM intervention group receive
one general message, one blood pressure related message, one glucose control message, one lifestyle modification message, one medication adherence message and one physical activity message per week (Table 3).

Initially, a test message was sent to each participant to ensure that the correct mobile phone number had been recorded and the system was functioning appropriately. All participants received a personalized welcome message, a follow-up reminder and a birthday greeting while enrolled in the study. Most of the text messages were developed to be unidirectional and participants are not anticipated to reply, however bidirectional text messages, checking on medication adherence and blood pressure/glucose level measurements, are sent at weekly intervals to evaluate patient engagement. Throughout the 6-month follow-up, research staff call participants if they do not respond for two consecutive weeks, and only one call is made per patient during the intervention period, so as not to confound the intervention.

**Procedures for Data Collection and Management**

**Data Collection**

Basic and contact information (ID number, address, and phone number), anthropometric data (waist circumference, height and weight), resting blood pressure, heart rate, ambulatory blood pressure, and information on socioeconomic status, risk factor control and current medications were collected at baseline at hospital recruitment sites. Detailed information on patient outcomes (hospitalizations, discharge diagnoses, etc.) was also collected during the survey and hospital records or death certificates obtained
where necessary for adjudication. Additional assessments of baseline medication adherence (Morisky Medication Adherence Scales: MMAS-8),\textsuperscript{37} physical activity (International Physical Activity Questionnaire: IPAQ),\textsuperscript{38, 39} CVD-specific health status (Seattle Angina Questionnaire: SAQ),\textsuperscript{40} health status (EuroQol five-dimensional questionnaire: EQ-5D),\textsuperscript{41} and smoking status were also conducted in person. Lastly, blood and urine samples were collected for local lab tests and eventual transfer to the core lab in Beijing at the biobank of NCCD. Laboratory values including low-density lipoprotein cholesterol (LDL-C) and glycemic hemoglobin (HbA\textsubscript{1C}) are assessed centrally. Follow-up information is conducted at 6 months by personal interviewing with research staff again collecting the information above (Table 4).

**Data Management**

A proprietary software platform was developed by the study IT team for use in sending text messages to participants. The platform is capable of sending tailored and semi-personalized text messages to participants and also recording responses. Additionally, this web-based platform can also serve to monitor project progress, as well as provide management support for hospitals, staff members, equipment and sampling materials. Trained medical staff members fill out pre-designed on-screen case report forms at each site, and data is then securely transmitted to the central server through automatic electronic transfer. To ensure the reliability and validity of the data, continuous checks are run to ensure that data being entered are complete and meet predefined data formats and ranges. The database is regularly backed-up and password protected so that only a limited number of approved staff members can access the data. In order to ensure the confidentiality of all personal
information, data confidentiality policies of the NCCD on data collection, storage and analysis have been strictly imposed.

**Outcomes**

In CHAT study, the primary outcome is the change in systolic blood pressure (SBP) after 6 months. Secondary outcomes include a change in proportion of patients achieving SBP<140mm Hg, LDL-C, physical activity, medication adherence, body mass index (BMI), and smoking cessation. Exploratory outcomes include the prognosis of the patients at 6 months, such as death, non-fatal myocardial infarction, stroke and any re-hospitalization, as well as health status measured by SAQ and EQ-5D.

In CHAT-DM study, the primary outcome is the change in glycemic hemoglobin (HbA$_{1C}$) as measured by central blood sample. Secondary outcomes include a change in proportion of patients achieving HbA$_{1C}$$<$7%, fasting blood glucose, SBP, LDL-C, BMI, physical activity and medication adherence. Exploratory outcomes include prognosis of patients at 6 months, including death, nonfatal myocardial infarction, stroke and any re-hospitalization, as well as health status (SAQ and EQ-5D).

Blood pressure is measured on the right upper arm after 5 minutes of rest in a seated position using an electronic blood pressure monitor (Omron HEM-7111; Omron Corporation, Dalian, China). Two measurements are taken and the mean value is calculated. If the difference between the two SBP or diastolic blood pressure (DBP) readings is larger than 5 mm Hg, a third measurement is
done, and the mean value of the last two readings is calculated. HbA1C is
determined using a high-performance liquid chromatography technique with
ADAMS™A1cHA-8180 (ARKRAY, Inc, Japan). BMI is calculated by dividing
weight in kilograms by height in meters squared. Physical activity is measured
in metabolic equivalents of task (METs) per minute per week, using the short
version of the IPAQ.38,39 Medication is assessed via MMAS-8, which scores
the adherence from 0 to 8 points.37 Smoking status is determined using either
self-reported smoking status or urine-cotinine testing strip with a cut-off of
200ng/mL cotinine (COT Cotinine Test Colloidal Gold; Hangzhou Clongene
Biotech Co., China).42,43 Quality of life is measured using Short Version of
SAQ40 and EQ-5D.41

Statistical Analysis

Intervention evaluation will be carried out on an intention-to-treat (ITT) basis.
Values of analyzed endpoints between intervention group and control group
will be compared using Student’s t-tests for continuous variables or Chi-square
tests for categorical variables according to the analysis plan. Mann-Whitney U
tests will be used where continuous data are not normally distributed. The
mean level of each risk factor will also be compared between groups in terms
of relative risks, 95% CIs and two-sided p values for achieving the guideline
level of each risk factor. We will follow prespecified analysis plan and subgroup
analysis will be conducted accordingly.

All sample size calculations in both studies are for 80% power and 0.05
(one-sided) level of significance, allowing for 20% dropout rate during follow up.
In CHAT study, we estimate a mean SBP level of 132mm Hg [SD, 18mm Hg] in the control group according to the report of previous studies, and assume an absolute reduction in SBP of 5 mm Hg at 6 months from baseline. Considering the compliance during the study intervention period, it was estimated that the mean SBP reduction in intervention group would be smaller. A total sample size of 790 patients was computed to detect a difference in SBP of 3.5mm Hg between two groups. In CHAT-DM study, we assume a mean HbA\(_1C\) level of 7.2% [SD, 1.6%] based on data from studies involving similar populations and supposed a 0.5% absolute decrease in HbA\(_1C\) across treatment group. A total sample size of 480 patients was estimated to detect a difference in HbA\(_1C\) of 0.4% between groups considering the potential compliance during the study. The trial results will be reported in accordance with the SPIRIT checklists.

**ETHICS AND DISSEMINATION**

The findings of the study will be disseminated by standard scientific forums, including peer-review publications and presentations at conferences. The central ethics committee at the China National Center for Cardiovascular Disease (NCCD) approved the CHAT and CHAT-DM studies. All collaborating hospitals accepted the central ethics approval except for 8, which obtained local approval by internal ethics committees. The Chinese government, which provides financial support, has no role in the design or conduct of the study, the collection, management, analysis, and interpretation of the data; or in the preparation or approval of articles resulting from the studies.
DISCUSSION

The CHAT and CHAT-DM studies aim to assess the efficacy of an innovative solution for improving secondary prevention of CHD by using simple and cost-effective text-messaging technology among patients with known CHD, with or without DM, throughout China. To the best of our knowledge, these two trials are the first to investigate the efficacy of text messages to support management of CHD and DM among a large population in China, and may set a model of such interventions that can be leveraged to improve risk factor management in resource-constrained settings.

The CHAT and CHAT-DM studies have several strengths. Few trials have addressed the role of text messages in managing multiple risk factors in patients with CHD or DM. Targeting multiple risk factors concurrently instead of managing a single risk factor may be more efficient and impactful on disease management as this strategy is more patient-centric than disease-centric, and have a greater likelihood of improving risk factor control and cardiovascular outcomes.\textsuperscript{47, 48} Additionally, there is currently little evidence about the effectiveness of such interventions for high-risk patients with coronary heart disease and diabetes.

The CHAT and CHAT-DM studies are further distinguished by their large sample sizes and culturally appropriate, theory-driven text messages. Most text message intervention studies that have focused on health behavior or diabetes management have had sample sizes ranging from 18-357 participants.\textsuperscript{49} CHAT has a sample size of around 790 while the sample size of
CHAT-DM is 480. It is noteworthy that CHAT is the first study using theory-based text messaging as a method of delivery for CHD patients’ behavior change in China. Data from other text messaging intervention studies suggest that text messaging programs achieved better results when message content is theory-based, however, few text messaging studies specified a theoretical rationale. Further, text messages were tailored to a specific Chinese patient population. Studies have found that the majority of Chinese adults prefer learning by following directive rules and guidelines, and practical counseling instructions were provided through text messages to help them better modify health behaviors. Apart from this, the text message language was designed to be plain and easy to memorize, consistent with Chinese cultural features such as aphorism, chengyu and catchy rhyme schemes, making it more acceptable to patients.

The two studies have several additional strengths. In contrast to most prior single center text-messaging trials, these two studies are conducted at 37 participating sites spread across a large and geographically diverse country, the results of which may be more generalizable. Moreover, our research team devoted significant attention to quality data collection, including rigorous on-site monitoring of questionnaire answers, samples collection, and data management. Furthermore, an evaluation of the acceptability and feasibility of our text message-based intervention will provide further important evidence to inform future studies, particularly with regards to optimizing text content, text frequency, and the overall user experience.

Our study also has some potential limitations. First, medication adherence and physical activity are measured by self-report, which carries the possibility of
recall bias and social desirability bias. However, we believe that any such bias would be balanced across the treatment and control groups, and MMAS-8 and IPAQ have been validated and widely used in measuring this metric. Second, the text messages, though semi-personalized, were not tailored specifically to every individual, which may reduce their efficacy. These questions might be addressed in future studies using more individualized messages.

The CHAT and CHAT-DM studies have important public health implications. As low cost, non-pharmacological interventions, the CHAT and CHAT-DM studies may serve as important models for patient-centered, evidence-based public health interventions. LMICs, including China, face challenges with huge burdens of CVD and DM, limited health resources, and geographically and culturally diverse patient populations, making them the ideal places to conduct such studies. Still, high levels of mobile phone ownership across countries and income levels signal a promising new avenue for clinical research and that it may be possible to scale effective mobile health interventions for delivery to large populations in the coming years. If this innovative and simple prevention were proven to help, considering the low marginal cost and anticipated minimal adverse events, even with very modest effects, its benefits would be substantial in a country as large and populous as China.

In conclusion, the CHAT and CHAT-DM studies are multi-center, randomized controlled trials that are being conducted at 37 hospitals in China, and will thoroughly test the efficacy of text-messages to support secondary prevention for CHD and DM in LMICs. The studies targeted high-risk patient populations with a culturally-sensitive, scalable and cost-effective text-message intervention, went through comprehensive data collection and rigorous data
management, and have the potential to provide novel insights into disease management and be scaled-up to improve health in over a thousand patients in future.

Acknowledgments: We appreciate the multiple contributions made by study teams at the China Oxford Centre for International Health Research and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation in the areas of study design and operations, particularly the contributions to the text message bank by Xuekun Wu, Si Xuan and Xiuling Wang, and data collection and analysis by Ying Sun, Chaoqun Wu, Xueke Bai, Jiamin Liu and Wuhanbilige Hundei. We appreciate the valuable advice from Clara Chow and her team in Sydney, Weigang Zhao, Geng Liu, Yuanlin Guo, Zho Xu and Zengwu Wang. We are also grateful for the support provided by the Chinese government.


Funding: This project was supported by the Research Special Fund for Public Welfare Industry of Health (201202025, 201502009) from the National Health and Family Planning Commission of China, the National Key Technology R&D Program (2013BAI09B01, 2015BAI12B01, 2015BAI12B02) from the Ministry of Science and Technology of China and the 111 Project (B16005). Dr Spatz is
supported by grant K12HS023000 from the Agency for Healthcare Research and Quality Patient-Centered Outcomes Research Institute (PCORI) Mentored Career Development Program. The sponsors had no role in the preparation or approval of the manuscript.

**Competing interests:** Dr. Krumholz is a recipient of research agreements from Medtronic and from Johnson & Johnson (Janssen), through Yale University, to develop methods of clinical trial data sharing. He is also the recipient of a grant from the Food and Drug Administration and Medtronic to develop methods for post-market surveillance of medical devices; and is the founder of Hugo, a personal health information platform. The other authors have no potential conflicts to disclose.

**Ethical approval:** The central ethics committee at the China National Center for Cardiovascular Disease (NCCD) approved the CHAT and CHAT-DM studies. All collaborating hospitals accepted the central ethics approval except for 8, which obtained local approval by internal ethics committees.

**REFERENCES**


25. Arora S, Peters AL, Burner E, etc. Trial to examine text message-based mHealth in emergency department patients with diabetes (TExT-MED): a


40. Chan PS, Jones PG, Arnold SA, etc. Development and validation of a


Figure Legends

Figure 1. Geographic distribution of sites in CHAT and CHAT-DM studies

Figure 2. Text Development Process
# Table 1. Behavior change techniques used in message development and example messages

<table>
<thead>
<tr>
<th>Behavior change technique</th>
<th>Content/explanation</th>
<th>Example text message in Chinese and English</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide information</td>
<td>General information about behavior-health</td>
<td>The way you cook can impact your health as well. Steaming, boiling and sautéing are better ways to cook than deep-frying and pan frying. Cooking in less oil is a healthy alternative.</td>
</tr>
<tr>
<td>Prompt barrier identification</td>
<td>Identify barriers to performing the behavior and plan ways of overcoming them</td>
<td>Taking diabetes medications and injecting insulin regularly can help control your blood sugar. Forgetting to take your medication? Try to set a repeating alarm on your cell phone to remind you to take your medication or insulin injection.</td>
</tr>
<tr>
<td>Set graded tasks</td>
<td>Set easy tasks, and increase difficulty until target behavior is reached.</td>
<td>Have you been finding it hard to quit smoking? In the beginning things are always hard. You can use a schedule to gradually reduce the number of cigarettes you smoke. For example, you</td>
</tr>
</tbody>
</table>
may try going from 20 cigarettes to 15 per day for a week.

**Provide instruction**
- Telling the person how to perform a behavior and/or preparatory behaviors
- If you experience symptoms of angina (severe chest pain), place one nitroglycerin tablet under your tongue. Sit, stay calm and rest if you ever forget medications while going out. If angina symptoms are not relieved within 10 minutes, seek medical attention immediately.

**Prompt self-monitoring**
- The person is asked to keep a record of specified behavior(s).
- A cold or diarrhea will make your blood sugar levels rise, so monitor your glucose more frequently when you are sick. If you are using insulin, test your blood glucose 6-8 times a day, keep a blood glucose log and share it with your health providers.

**Prompt practice**
- Prompt the person to rehearse and repeat the behavior or preparatory behaviors
- As an old Chinese saying goes, ‘It takes more than one cold day for a river to freeze three feet deep; ice in the river takes a long time to melt.’ Similarly, cerebrovascular disease requires
long-term prevention and treatment. Remember to take your medications as prescribed!

Plan social support or social change

Prompting consideration of how others could change their behavior to offer the person help or (instrumental) social support.

Quitting smoking on your own can be difficult. Tell your friends and family when you are quitting so that they will stop giving you cigarettes. Support and encouragement from your loved one can be helpful as well.

Stress management

May involve a variety of specific techniques (e.g., progressive relaxation) that do not target the behavior but seek to reduce anxiety and stress.

Relaxation is something we need to learn and practice. Listening to music, reading, or talking to friends and family can ease stress.

Motivational interviewing

Prompting the person to provide self-motivating statements and

Did you smoke less today than you did yesterday or days before?

If you did reduce the amount of cigarettes, it is something worth
evaluations of their own behavior to minimize resistance to change celebrating. We are sure that you have put a lot of effort into quitting. Keep up the good work and you can make a difference!
Table 2. Survey scores for various message categories in user test

<table>
<thead>
<tr>
<th>Category</th>
<th>Strongly agree or agree</th>
<th>Neutral</th>
<th>Strongly disagree or disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General health messages</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=142)</td>
<td>130 (91.6%)</td>
<td>6 (4.2%)</td>
<td>6 (4.2%)</td>
</tr>
<tr>
<td>Information was useful (n=142)</td>
<td>129 (90.9%)</td>
<td>9 (6.3%)</td>
<td>4 (2.8%)</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=181)</td>
<td>168 (92.8%)</td>
<td>7 (3.9%)</td>
<td>6 (3.3%)</td>
</tr>
<tr>
<td>Information was useful (n=181)</td>
<td>169 (93.4%)</td>
<td>6 (3.3%)</td>
<td>6 (3.3%)</td>
</tr>
<tr>
<td><strong>Medication Adherence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=149)</td>
<td>134 (89.9%)</td>
<td>10 (6.7%)</td>
<td>5 (3.4%)</td>
</tr>
<tr>
<td>Information was useful (n=149)</td>
<td>137 (92.0%)</td>
<td>10 (6.7%)</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td><strong>Physical Activity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=116)</td>
<td>109 (93.9%)</td>
<td>6 (5.2%)</td>
<td>1 (0.9%)</td>
</tr>
<tr>
<td>Information was useful</td>
<td>111 (95.7%)</td>
<td>4 (3.4%)</td>
<td>1 (0.9%)</td>
</tr>
</tbody>
</table>
(n=116)

Smoking cessation

Information easy to understand (n=42)

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>1 (2.4%)</td>
</tr>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Information was useful (n=42)

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>
Table 3. Example Text Messages for the CHAT and CHAT-DM Studies

<table>
<thead>
<tr>
<th>CHAT TEXT [6 texts/wk]</th>
<th>CHAT-DM TEXT [6 texts/wk]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Education (CVD) [2x/wk]</strong></td>
<td><strong>General Education (DM) [1x/wk]</strong></td>
</tr>
<tr>
<td>The most common risk factors for coronary artery disease are smoking, obesity, high blood pressure, high cholesterol and diabetes. However, most of them can be controlled in an appropriate way.</td>
<td>Diabetes is not terrible and there are many things you can do to prevent problems from diabetes, such as monitoring blood glucose, watching your diet, keeping fit, and taking pills regularly.</td>
</tr>
<tr>
<td><strong>Blood Pressure Control [2x/wk]</strong></td>
<td><strong>Blood Pressure Control [1x/wk]</strong></td>
</tr>
<tr>
<td>Most people do not experience any symptoms of high blood pressure. Do not stop taking blood pressure medication unless directed by your doctor. It is important for patients with hypertension to take medication diligently and to monitor their blood pressure on a regular basis.</td>
<td>Home Blood Pressure Monitoring is highly recommended! You can get an accurate picture of your heart health and understand daily changes in blood pressure, which is helpful for doctors to adjust medications for you.</td>
</tr>
<tr>
<td><strong>Medication Adherence [1x/wk]</strong></td>
<td><strong>Medication Adherence [1x/wk]</strong></td>
</tr>
<tr>
<td><strong>Do you have a problem remembering to take your blood pressure medications?</strong></td>
<td>If so, try to tell your family about your medicine schedule so they can remind you.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Talk to doctors about your concerns and any uncomfortable symptoms after taking pills.</strong></td>
<td>Let your doctor help you to find the right medication for you.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Physical Activity [1x/wk]</strong></th>
<th><strong>Physical Activity [1x/wk]</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>You can still choose low-intensity exercise even after heart attack, such as walking and Tai Chi, at a slower pace and stick to your exercise plan.</td>
<td>Try brisk walking – a convenient, safe and cost-effective way of exercising! It's good for your heart and will help control blood glucose.</td>
</tr>
<tr>
<td>Always consult your physician before beginning any exercise program.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Smoking Cessation [1x/wk]</strong></th>
<th><strong>Diabetes Management [1x/wk]</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you worry about your family having health problems because of your smoking? Quitting is an important choice you can make to benefit your family's health, too.</td>
<td>See a doctor before you travel. Always carry your diabetes medications and insulin, glucose meter, and strips, so that you can better monitor your glucose. Carry some hard candy and crackers to avoid low sugar.</td>
</tr>
<tr>
<td>Secondhand smoke can cause respiratory disease, lung cancer, and heart disease.</td>
<td></td>
</tr>
<tr>
<td>Life style intervention [1x/wk]</td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td></td>
</tr>
<tr>
<td>Individuals with diabetes should consume a balanced diet, and eat smaller but more frequent meals. Consider splitting your meal and save it for a snack later. Some healthy snack choices include tomatoes, cucumbers, and sugar-free biscuits.</td>
<td></td>
</tr>
</tbody>
</table>

* In CHAT, non-smokers receive two General Education messages per week, while smokers only receive one per week.

† In CHAT, only smokers receive smoking cessation messages.
<table>
<thead>
<tr>
<th>Information</th>
<th>Baseline</th>
<th>6 month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic and contact information</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Physical examination: BP, HR, waist</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>circumference, weight, height</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Ambulatory blood pressure</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Outcome</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Hospitalizations</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Current medications</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Medication adherence (Morisky)</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Physical activity (IPAQ)</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>CVD functional status (SAQ)</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Health status (EQ-5D)</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Risk factors control</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Urine cotinine/nicotine test</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Blood urine sample for core lab and local test</td>
<td>✔️</td>
<td>✔️</td>
</tr>
</tbody>
</table>
Figure 1. Geographic distribution of sites in CHAT and CHAT-DM studies

169x111mm (96 x 96 DPI)
Figure 2. Text Development Process
Supplementary Materials

Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

TABLE OF CONTENTS

Page 2-3: CHAT and CHAT-DM studies site investigators by hospital
CHAT and CHAT-DM studies site investigators by hospital

1. China-Japan Union Hospital of Jilin University, Ping Yang, Zhaohui Feng, Mei Ding, Bing Li;
2. Dongfeng County Hospital, Wei Liu, Xiaoxin Li, Yanbin Zhang, Wen Cui, Sen Shi;
3. First Hospital of Shanxi Medical University, Qinghua Han, Liqin Duan, Chunrong Jin;
4. General Hospital of China FAW Group Corporation, Hongtao Pan, Lei Sun, Peng Chen;
5. Inner Mongolia Baogang Hospital, Yongdong Li, Liqing Jia, Xingxing Ren;
6. Jiangxi Provincial People’s Hospital, Lang Hong, Ji Hong, Linfeng Li, Lihua Yuan, Yun Li;
7. Laixi People’s Hospital, Xu Jiang, Hui Liu, Guohao Xu, Yanrong Song;
8. Laoting County Hospital, Keyong Shang, Changjiang Liu, Kuituan Xi, Ying Yu;
9. Lujiang County People’s Hospital, Keliang Xu, Cunqi Wang, Yongan Qian;
10. Nanyang Central Hospital, Shouzhong Yang, Yudong Li, Jianbu Gao, Songyu Zhang;
11. Port Hospital of Hebei Port Group Company, Ltd, Xia Wu, Penghui Yang, Xueqing Wang;
12. Qingdao Fuwai Hospital, Xianyan Jiang, Bin Zhang, Yumei Dong, Cheng Zheng, Wenchuan Hu;
13. Qinghai Cardiovascular and Cerebrovascular Hospital, Huiping Bian, Bo Chen, Xiaojuan Han, Na Han;
14. Qinzhou Second People’s Hospital, Liyuan Chen, Qiuxia Liu, Lin Chen;
15. Quwo County People’s Hospital, Xiwu Wang, Zhenlin Wu, Qiang Wang, Zhaohui Shangguan;
16. Shanxi Cardiovascular Hospital, Bin Yang, Yingsheng Yang;
17. Shenyang the Fourth Hospital of People, Yinjun Li, Wei Jiang;
18. Shuangcheng People’s Hospital, Cheng Zhang, Aiguo Sun, Xuemei Wang;
19. Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Feng Liu, Qiaoxia Zhou, Bingbing Zhu, Jie Guo;
20. The Affiliated Hospital of Qingdao University, Changyong Zhou, Yini Wang, Tao Yu, Zhe Su;
21. The First Affiliated Hospital of Fujian Medical University, Jinxiu Lin, Dajun Chai, Qinghui Guo;
22. The Affiliated Hospital of Xuzhou Medical University, Dongye Li, Yuanyuan Luo, Junhong Chen, Wei Qian, Qian Yu, Lulu Sun;
23. The First Hospital of Jilin University, Yang Zheng, Zhaoxi Liu, Lin Zou;
24. The Fourth Affiliated Hospital of China Medical University, Yuanzhe Jin, Xiaohong Zhang, Weina Hu;
25. The people’s hospital of Dongxihu district of Wuhan, Yongbo Lin, Ling Zhou, Hanliang Dan;
26. The People’s Hospital of Liaoning Province, Zhanquan Li, Ying Liu, Dan Li;
27. The Second Affiliated Hospital of Xuzhou Medical College, Weihe Wu, Li Li, Sai Zhang;
28. The Second Affiliated Hospital of Zhengzhou University, Xian Fa, Lihua Zhang, Liqiang Sun, Youxu Jiang;
29. Tianjin Medical University General Hospital, Yuemin Sun, Bo Bian;
30. TEDA International Cardiovascular Hospital, Zhigang Liu, Zhipeng Guo, Cun Zhang;
31. Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Jiangang Jiang, Xiaoqing Shen, Ting Yu;
32. Wuhan Asia Heart Hospital, Xi Su, Songzhi Zhao, Wei Wu, Yujing Fan;
33. Wulate County People's Hospital, Jinlan Xu, Lei Xia, Yunmei Wang;
34. Xiangtan Central Hospital, He Huang, Jianping Zeng, Mingxing Wu, Yi Zhou;
35. Xinmin People's Hospital, Bo Jiang, Liwei Qi, Tongying Li;
36. Xuzhou First People's Hospital, Hongju Zhang, Chen Bian, Wei Li;
37. Zhengzhou Central Hospital, Lin Zhang, Yumei Guo;
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>N/A</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>N/A</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>21</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>1-2</td>
</tr>
<tr>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>6, 22</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>22</td>
</tr>
</tbody>
</table>
Introduction

Background and rationale

6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention

4-6

6b Explanation for choice of comparators

8

Objectives

7 Specific objectives or hypotheses

5-6

Trial design

8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

6

Methods: Participants, interventions, and outcomes

Study setting

9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained

6

Eligibility criteria

10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)

7

Interventions

11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered

7-12

11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)

8

11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)

12

11d Relevant concomitant care and interventions that are permitted or prohibited during the trial

8

Outcomes

12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

14-15

Participant timeline

13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)

6
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations 15-16

Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 6

Methods: Assignment of interventions (for controlled trials)

Allocation:

 Sequence generation 16a Method of generating the allocation sequence (e.g., computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (e.g., blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions 7

 Allocation concealment mechanism 16b Mechanism of implementing the allocation sequence (e.g., central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 7

 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions 7

 Blinding (masking) 17a Who will be blinded after assignment to interventions (e.g., trial participants, care providers, outcome assessors, data analysts), and how 7

 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial N/A

Methods: Data collection, management, and analysis

 Data collection methods 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (e.g., duplicate measurements, training of assessors) and a description of study instruments (e.g., questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol 12-13

 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols N/A
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality (e.g., double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol 13-14

Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol 15-16

20b Methods for any additional analyses (e.g., subgroup and adjusted analyses) 16

20c Definition of analysis population relating to protocol non-adherence (e.g., as randomised analysis), and any statistical methods to handle missing data (e.g., multiple imputation) 15

Methods: Monitoring

Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed N/A

21b Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial N/A

Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct 13

Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor N/A

Ethics and dissemination

Research ethics 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 6

Protocol amendments 25 Plans for communicating important protocol modifications (e.g., changes to eligibility criteria, outcomes, analyses) to relevant parties (e.g., investigators, REC/IRBs, trial participants, trial registries, journals, regulators) N/A
<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>26a</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how</td>
<td>6</td>
</tr>
<tr>
<td>26b</td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
<td>6</td>
</tr>
<tr>
<td>27</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>13-14</td>
</tr>
<tr>
<td>28</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>21</td>
</tr>
<tr>
<td>29</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>12-14</td>
</tr>
<tr>
<td>30</td>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation</td>
<td>N/A</td>
</tr>
<tr>
<td>31a</td>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions</td>
<td>20</td>
</tr>
<tr>
<td>31b</td>
<td>Authorship eligibility guidelines and any intended use of professional writers</td>
<td>21</td>
</tr>
<tr>
<td>31c</td>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code</td>
<td>20</td>
</tr>
</tbody>
</table>

**Appendices**

- **Informed consent materials**
  - Model consent form and other related documentation given to participants and authorised surrogates | N/A |

**Bibliography**

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license.*
Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

<table>
<thead>
<tr>
<th>Journal:</th>
<th>BMJ Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bmjopen-2017-018302.R1</td>
</tr>
<tr>
<td>Article Type:</td>
<td>Protocol</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>13-Sep-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Huo, Xiqian; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease
Spatz, Erica; Yale University
Ding, Qinglan; Yale University
Horak, Paul; Yale University
Zheng, Xin; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease
Masters, Claire; Yale University
Zhang, Haibo; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research
Irwin, Melinda; Yale School of Public Health
Yan, Xiaofang; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease
Guan, Wenchi; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research
Li, Jing; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research
Li, Xi; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease
Spertus, John; Mid America Heart Institute of Saint Luke’s Hospital
Masoudi, Frederick; Division of Cardiology, University of Colorado Anschutz Medical Campus
Krumholz, Harlan; Yale School of Public Health
Jiang, Lixin; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease |
| Primary Subject Heading: | Research methods |
| Secondary Subject Heading: | Research methods, Medical management |
| Keywords: | Coronary heart disease < CARDIOLOGY, diabetes, text messaging, behavioral intervention, secondary prevention |
Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

Xiqian Huo, MD*; Erica S. Spatz, MD, MHS*; Qinglan Ding, MS; Paul Horak, BS; Xin Zheng, MD, PhD; Claire Masters, MHP; Haibo Zhang, MD; Melinda Irwin, PhD, MPH; Xiaofang Yan, MD; Wenchi Guan, MD; Jing Li, MD, PhD; Xi Li, MD, PhD; John A. Spertus, MD, MPH; Frederick A. Masoudi, MD, MSPH; Harlan M. Krumholz, MD, SM**; Lixin Jiang, MD, PhD**

(* Joint first authors)  
(** Joint senior authors)

China Oxford Center for International Health Research, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China (X.H, X.Z, H.Z, X.Y, W.G, J.L, X.L, L.J);  
Center for Outcomes Research and Evaluation, Yale University/Yale-New Haven Hospital, New Haven, Connecticut, USA (E.S.S, Q.D, P.H, C.M, M.I, H.M.K);  
Health Outcomes Research, Saint Luke’s Mid America Heart Institute/University of Missouri-Kansas City, Kansas City, Missouri, USA (J.A.S);
Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA (F.A.M).

Correspondence: Lixin Jiang, MD, PhD, National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, 167 Beilishi Road, Xicheng District, Beijing, 100037, People’s Republic of China. Tel: +86 10 8839 6203; Fax: +86 10 8836 5201. Email: jiangl@fwoxford.org

ABSTRACT

Introduction: Mobile health interventions have the potential to promote risk factor management and lifestyle modification, and are a particularly attractive approach for scaling across healthcare systems with limited resources. We are conducting two randomized trials to evaluate the efficacy of text-based health messages in improving secondary coronary heart disease (CHD) prevention among patients with or without diabetes.

Methods and analysis: The Cardiovascular Health And Text messaging (CHAT) and CHAT-Diabetes Mellitus (CHAT-DM) Studies are multi-center, single-blind, randomized controlled trials of text messaging versus standard treatment with 6 months of follow-up conducted in 37 hospitals throughout 17 provinces in China. The intervention group receives 6 text messages per week which target blood pressure control, medication adherence, physical activity, smoking cessation (when appropriate), glucose monitoring and lifestyle
recommendations including diet (in CHAT-DM). The text messages were
developed based on behavioral change techniques, using models such as
information-motivation-behavioral skills model, goal-setting and provision of
social support. The estimated sample size is 790 in CHAT Study and 480 in
CHAT-DM Study. In CHAT, the primary outcome is the change in systolic blood
pressure (SBP) at 6 months. Secondary outcomes include a change in
proportion of patients achieving a SBP<140mm Hg, low-density lipoprotein
cholesterol (LDL-C), physical activity, medication adherence, body mass index
(BMI), and smoking cessation. In CHAT-DM, the primary outcome is the
change in glycemic hemoglobin (HbA1C) at 6 months. Secondary outcomes
include a change in proportion of patients achieving HbA1C<7%, fasting blood
glucose, SBP, LDL-C, BMI, physical activity and medication adherence.

Ethics and dissemination: The central ethics committee at the China
National Center for Cardiovascular Disease (NCCD) approved the CHAT and
CHAT-DM studies. Results will be disseminated via usual scientific forums
including peer-reviewed publications.

Trial registration number: CHAT (NCT02888769) and CHAT-DM
(NCT02883842); pre-results.

KEYWORDS: coronary heart disease, diabetes, text messaging, behavioral
intervention, secondary prevention
Strengths and Limitations of study:

1. The main strengths of the study are that it evaluates the efficacy of an innovative, simple, scalable and cost-effective intervention for improving secondary prevention of CHD. The trials are the first to investigate the effectiveness of text messages to support management of CHD and DM among a large and diverse population in China, and have the potential for scaling across healthcare systems in resource-constrained settings.

2. The study addressed the role of text messages in managing multiple risk factors in patients with CHD or DM. Moreover, there is currently little evidence about the effectiveness of such interventions for high-risk patients with coronary heart disease and diabetes.

3. The CHAT and CHAT-DM studies are further distinguished by their relative large sample sizes and culturally appropriate, theory-driven text messages. The messages were developed using behavior change technique and tailored to a specific Chinese patient population.

4. In contrast to most prior single center text-messaging trials, these two studies are conducted at 37 participating sites spread across a large and geographically diverse country. The results of the studies may be more generalizable.

5. However, medication adherence and physical activity are measured by self-report, which carries the possibility of recall bias and social desirability bias.
INTRODUCTION

The benefits of secondary prevention strategies for coronary heart disease (CHD) targeting lifestyle modification and risk factor management are well-established worldwide,\(^1\,\,2\) however adoption of these strategies is suboptimal.\(^3\) Smoking, inactivity and obesity are prevalent among people with established CHD and control of hypertension and diabetes are often suboptimal. Additionally, medication adherence is poor. Prior studies revealed that only three-fourths of patients take all medications from their discharge prescriptions by 120 days after discharge.\(^4\) Furthermore, less than half of patients hospitalized with acute myocardial infarction (AMI) are adherent to evidence-based medications 1 year later, with the greatest gaps in adherence occurring in the first 6 months after treatment initiation.\(^5\,\,7\)

In lower and middle-income countries (LMICs), including China, which face a growing burden of cardiovascular disease and greater challenges to medication access for secondary prevention, over two-thirds of patients with CHD take no medication.\(^8\,\,10\) While high medication costs are a barrier,\(^11\) there is also limited time for education and consultation regarding lifestyle and medication management during clinic visits, which tend to be very brief.\(^12,\,13\) Therefore, innovative and cost-effective interventions to enhance adherence are urgently needed.

Mobile phones are pervasive and thus can be used to deliver interventions that help people to adopt secondary prevention strategies for CHD in LMICs. They are already a primary, inexpensive and quick form of communication, and are also widely used to schedule alerts and reminders. In addition, the number of
Mobile phone users has grown exponentially in the past decade worldwide, and is projected to reach 4.77 billion by 2017.\textsuperscript{14} As of August 2016, China had the largest number of mobile phone owners in the world, at 1.3 billion.\textsuperscript{15} Mobile phones are also used across all geographic regions and income levels. Due to the ubiquity and convenience, nearly 200,000 mobile phone messages are sent every second in China.\textsuperscript{16} Text messaging has the potential to be a scalable and powerful tool to deliver health information.\textsuperscript{17, 18}

Prior studies of mobile phone text messaging have been conducted to improve glycemic control,\textsuperscript{19} hypertension,\textsuperscript{20} medication adherence,\textsuperscript{21} as well as to promote smoking cessation,\textsuperscript{22} and physical activity.\textsuperscript{23, 24} These trials have contributed important knowledge, and some, such as TEXT-ME\textsuperscript{25} and TExT-MED\textsuperscript{26} suggest that text-messaging interventions can influence patient behaviors and improve risk profiles. Still, several questions remain about the generalizability of these findings, especially for populations from LMICs. Most trials to date have been designed to target a single condition; yet patients with cardiovascular disease usually manage multiple conditions, requiring several lifestyle and treatment recommendations. Additionally, most studies of text messaging interventions have not been grounded in behavioral change techniques (BCT),\textsuperscript{27, 28} which may influence the efficacy and generalizability of the intervention. Finally, most prior studies have been limited to single site interventions, many of which were underpowered and/or limited by selection bias. More data are needed to understand whether text-messaging interventions should be adopted as an effective strategy for supporting cardiovascular disease prevention among diverse populations from LMICs.\textsuperscript{29}
Accordingly, we designed and conducted the Cardiovascular Health And
Texting (CHAT) and CHAT-Diabetes Mellitus (CHAT-DM) studies. The primary
objective of these two studies is to evaluate the efficacy of an automated text
message-based intervention, based on behavioral change techniques, in
improving risk factor control and adoption of healthy lifestyle behaviors among
patients with known CHD, with or without DM, who were discharged from
multiple hospitals throughout China.

METHODS AND ANALYSIS

Study Overview

The CHAT and CHAT-DM studies are multi-center, single-blind, 2-arm,
randomized controlled trials of an automated mobile phone text
message-based intervention with 6 months of follow-up. Patients were
recruited from 37 hospitals across 17 provinces in China (Figure 1,
supplementary material). The enrollment of participants began on August 16,
2016. The two studies were registered at http://www.clinicaltrials.gov
(NCT02888769 and NCT02883842) accordingly. We retrospectively registered
the trial 7 days in CHAT and 5 days in CHAT-DM study after enrollment of the
first patient, beyond what is recommended by ICMJE that trials registry at or
before the time of first patient enrollment, as we referred to the FDA AA801
public law on the Clinicaltrials.gov website that clinical trials are registered no
later than 21 days after the first patient was enrolled. The recruitment was
completed in April 2017, and the last follow-up visit is expected to finish in
October 2017. All participants provided written informed consent at the initial
trial visit.

### Study Population

In CHAT, patients were eligible if they had established CHD defined as having a history of AMI and/or percutaneous coronary intervention (PCI), having access to a mobile phone to read and send text messages, and did not have diabetes. In CHAT-DM, patients were eligible if they had a history of documented CHD (as defined in CHAT) and diabetes, and had access to a mobile phone to read and send text messages. In both studies, patients were excluded if they could not read or send text messages, had cognitive or communication disorders, or could not provide informed consent. A ‘screening log’ of basic demographic information and reasons for not participating in patients deemed ineligible but who declined to participate has been maintained. We recruited patients who had been hospitalized with CHD, with or without DM, and had medical records with definite discharge diagnoses available. The diagnoses of CHD and DM given by local physicians were adjudicated centrally, based upon review of the patients’ medical charts, which were sent to the China National Center for Cardiovascular Disease (NCCD).

### Randomization and blinding

Participants were randomly allocated to either the intervention or control arms in a 1:1 ratio using a computerized randomization system. In order to achieve a balance of participants’ characteristics in both arms, we employed a stratified
randomization approach, based on age, gender, AMI history, education
degree and medical insurance type within each study. Researchers,
statisticians and clinic staff were blinded to treatment allocation.

Trial intervention

Participants in the intervention groups of the CHAT and CHAT-DM studies
receive text messages about CHD risk factor modification for 6 months as well
as standard treatment (described below). The control group in both studies
receive two thank-you text messages without risk factor modification support
each month as well as standard treatment. A training session was held by
research staff upon enrollment to ensure that all participants were capable of
receiving, reading and sending text messages on their mobile phones. Prior to
commencement, a test message was sent to each participant to confirm the
phone number and that the system was working effectively. Whether the test
messages had reached the patients would be recorded by local study staff,
and if patients did not receive messages, local study staff would confirm and
update the correct phone number. Participants were also informed that they
could withdraw from the study by responding to a text message with a specific
character. Researchers at NCCD could monitor the status of text message
delivery, review responses sent by participants and manage withdrawal via a
customized software platform. For instance, logs were kept to assess the
proportion of text messages successfully delivered, the exact time of
messages being sent and the reasons for those that failed to be sent.
CHAT and CHAT-DM intervention development

A bank of 550 text messages (280 in CHAT and 270 in CHAT-DM) was developed by a multidisciplinary team of cardiologists, endocrinologists, psychologists, nurses and public health researchers using a three-phase systematic and iterative approach (Figure 2). In the CHAT study, text messages are categorized into five groups: (1) general education on CHD and AMI, (2) medication adherence, (3) blood pressure control, (4) physical activity, and (5) smoking cessation. The text messages in the CHAT-DM study cover a range of diabetes self-management topics including: (1) general education on CHD and DM, (2) medication adherence, (3) glucose monitoring and control, (4) blood pressure control, (5) physical activity, and (6) lifestyle recommendations such as diet and foot care. All text messages are in Chinese, and each text message is less than 70 Chinese characters, which would be equivalent to a 140-160-character message in English.

Phase 1 Approach to developing text messages

Text messages were originally drafted by members of the research team in Chinese based on current guidelines and standards of care pertaining to cardiovascular health and diabetes care. All messages were grounded in behavioral change techniques previously used to develop short health messages, providing information, goal-setting, motivation, social support and stress management advice. In order to strengthening the designing and reporting of theory-based BCT interventions, we took into account the two recent BCT taxonomies by Michie, S, and his colleagues. Efforts were devoted to selecting the behavioral change techniques most applicable to the
Chinese cultural context and compatible with Chinese beliefs and values (Table 1). For example, some text messages applied traditional Chinese aphorisms, chengyu, and catchy rhyme schemes in order to make them more acceptable to patients. As another example, in designing text messages that were motivating, especially in challenging situations, the multidisciplinary group felt that Chinese people tend to prefer more direct and structured counseling instructions rather than indirect and insight-oriented approaches (a category of psychotherapeutic approaches that promote individuals' adaptive behavior and course of action in life through understanding their internal motivation); as such, text messages were written to provide practical approaches and real-life examples instead of abstract theories. Social and family-oriented goals were used more often than individual achievement to help improve health behaviors, consistent with cultural norms in China. These messages were sent to experts in behavioral change techniques and counseling for review and were used as examples to draft the initial bank of 550 text messages. Once drafted, all messages were reviewed, critiqued and revised within the internal research team.

**Phase 2 Expert review**

An expert panel made up of clinicians and academics reviewed each round of text message drafts with a different focus in each iteration. First, clinical experts (cardiologists, endocrinologists and psychologists) considered the accuracy, clarity and practical usefulness of each text message. Second, messages from all categories in the CHAT and CHAT-DM studies text banks were randomly selected and translated into English by bilingual researchers. Experts in the fields of cardiology, endocrinology, epidemiology, psychology
and behavioral science in the U.S. reviewed them and provided suggestions for further refinement. Finally, Chinese researchers and a linguist reviewed all 550 text messages, further refined the language, and paid special attention to the cultural meaning of all text messages to ensure better understanding among the targeted population (elderly Chinese patients with cardiovascular disease, with and without diabetes). Once feedback from the experts was addressed, the text bank was updated and prepared for user testing.

8 Phase 3 User testing and pilot study

For user testing, 19 randomly selected text messages from the finalized text bank in the CHAT and CHAT-DM studies were distributed to 39 individuals with CHD (with or without diabetes) for feedback. Likert-type items in a survey were used to assess usefulness and ease of understanding of the text messages. Open-ended questions were asked to obtain suggestions for improvement from participants. In total, 92.4% (582/630) rated the messages as easy to understand and 93.2% (587/630) rated the messages as useful. All 550 text messages were further modified based on feedback from user testing. Results of the scores for the message categories in this phase are summarized in Table 2.

Next, the refined text message banks underwent pilot testing to evaluate the efficacy of the message delivery system and quality of the user experience. A customized software program sent messages through a gateway interface, allowing them to be sent to all individuals' mobile phones free of charge and at a bulk-rate cost (0.1 yuan per message, or .01 USD) to the research team. Participants from the user testing were enrolled in the pilot testing after
providing written informed consent (n=33). For the pilot study, messages
drawn from the entire text bank were sent to participants. At the end of the
1-month pilot study, 30 participants reported their experience of receiving
messages and commented on frequency, timing, content and potential impact
of text messages. Minor changes were made to the text message bank
following the pilot study based on this feedback.

Frequency and timing of text message delivery

Each participant in the intervention group of the CHAT and CHAT-DM studies
receives 6 text messages per week, randomly selected by the software system,
across a 6 month timeframe. The messages are sent at one of three random
times (9am, 12pm or 4pm), during weekends and weekdays (excluding
Monday to give people a break). The text messages were designed to be
semi-personalized with participant’s preferred name at beginning of some
messages, as well as considering participant’s smoking status. In the CHAT
study, participants receive two general education messages on CHD (one if an
active smoker), two blood pressure control messages, one medication
adherence message, and one physical activity message per week. Smokers
receive one smoking cessation message per week. Participants in the
CHAT-DM intervention group receive one general message, one blood
pressure related message, one glucose control message, one lifestyle
modification message, one medication adherence message and one physical
activity message per week (Table 3).

Initially, a test message was sent to each participant to ensure that the correct
mobile phone number had been recorded and the system was functioning
appropriately. All participants received a personalized welcome message, a follow-up reminder and a birthday greeting while enrolled in the study. Most of the text messages were developed to be unidirectional and participants are not anticipated to reply, however bidirectional text messages, checking on medication adherence and blood pressure/glucose level measurements, are sent at weekly intervals to evaluate patient engagement. Throughout the 6-month follow-up, research staff call participants if they do not respond for two consecutive weeks, and only one call is made per patient during the intervention period, so as not to confound the intervention.

Procedures for Data Collection and Management

Data Collection

Basic and contact information (ID number, address, and phone number), anthropometric data (waist circumference, height and weight), resting blood pressure, heart rate, ambulatory blood pressure, and information on socioeconomic status, risk factor control and current medications were collected at baseline at hospital recruitment sites. Detailed information on patient outcomes (hospitalizations, discharge diagnoses, etc.) was also collected during the survey and hospital records or death certificates obtained where necessary for adjudication. Additional assessments of baseline medication adherence (Morisky Medication Adherence Scales: MMAS-8), physical activity (International Physical Activity Questionnaire: IPAQ), CVD-specific health status (Seattle Angina Questionnaire: SAQ), health status (EuroQol five-dimensional questionnaire: EQ-5D), and smoking status
were also conducted in person. Lastly, blood and urine samples were collected for local lab tests and eventual transfer to the core lab in Beijing at the biobank of NCCD. To ensure the standardization and accuracy of the sample analysis results, we developed standard operating procedures and trained local study researchers repeatedly regarding samples collection, separation, storage and transfer process. Blood tests, including low-density lipoprotein cholesterol (LDL-C), glycemic hemoglobin (HbA1C) and fasting blood glucose (FBG) will be analyzed at central laboratory. Research staff would collect the above information again as listed in Table 4 at follow-up visit. We conducted on-site monitoring of recruitment, physical measurements, sample collection and document completeness (e.g. informed consent) by trained staff from NCCD to ensure the quality of data collection.

**Data Management**

A proprietary software platform was developed by the study IT team for use in sending text messages to participants. The platform is capable of sending tailored and semi-personalized text messages to participants and also recording responses. Additionally, this web-based platform is used to monitor project progress, as well as provide management support for hospitals, staff members, equipment and sampling collection and transfer. Trained medical staff members fill out pre-designed on-screen case report forms at each site, and data is then securely transmitted to the central server through automatic electronic transfer. To ensure the reliability and validity of the data, continuous checks are run to ensure that data being entered are complete and meet predefined data formats and ranges. The database is regularly backed-up and
password protected so that only a limited number of approved staff members

can access the data. In order to ensure the confidentiality of all personal

information, data confidentiality policies of the NCCD on data collection,

storage and analysis have been strictly imposed.

Outcomes

In the CHAT study, the primary outcome is the change in systolic blood

pressure (SBP) after 6 months. Secondary outcomes include a change in

proportion of patients achieving a SBP<140mm Hg, change in proportion of

non-smokers, change in medication adherence categorized by Morisky scale,

as well as change in plasma mean level of LDL-C, change in level of body

mass index (BMI) and change in level of physical activity. Exploratory

outcomes include the prognosis of the patients at 6 months, such as death,

non-fatal myocardial infarction, stroke and any re-hospitalization, as well as

health status measured by SAQ and EQ-5D.

In the CHAT-DM study, the primary outcome is the change in glycemic

hemoglobin (HbA1C) as measured by central blood sample. Secondary

outcomes include a change in proportion of patients achieving HbA1C<7%,

change in medication adherence, as well as change in mean level of FBG,

SBP, LDL-C, BMI and physical activity. Exploratory outcomes include

prognosis of patients at 6 months, including death, nonfatal myocardial

infarction, stroke and any re-hospitalization, as well as health status (SAQ and

EQ-5D).
Blood pressure is measured on the right upper arm after 5 minutes of rest in a seated position using an electronic blood pressure monitor (Omron HEM-7111; Omron Corporation, Dalian, China). Two measurements are taken and the mean value is calculated. If the difference between the two SBP or diastolic blood pressure (DBP) readings is larger than 5 mm Hg, a third measurement is done, and the mean value of the last two readings is calculated. HbA1c is determined using a high-performance liquid chromatography technique with ADAMS™A1c-HA-8180 (ARKRAY, Inc, Japan). BMI is calculated by dividing weight in kilograms by height in meters squared. Physical activity is measured in metabolic equivalents of task (METs) per minute per week, using the short version of the IPAQ. Medication is assessed via MMAS-8, which scores the adherence from 0 to 8 points. Smoking status is determined using either self-reported smoking status or urine-cotinine testing strip with a cut-off of 200ng/mL cotinine (COT Cotinine Test Colloidal Gold; Hangzhou Clongene Biotech Co., China). Quality of life is measured using Short Version of SAQ and EQ-5D. Local study staff obtained information of baseline hospitalization, readmissions to hospitals and death during the patient’s interview, with medical records, death certificates or death records collected as supporting documents. If the patient died at home without any evidentiary material, a structured summary of death conversation with family members would be reported. All information was sent to the NCCD for central adjudication according to pre-specified criteria by trained clinicians. If the patient was re-hospitalized in other hospitals, for example, the study investigators will contact the specific hospital, copy those medical records and transmit them to NCCD as required.
**Statistical Analysis**

3. Intervention evaluation will be carried out on an intention-to-treat (ITT) basis.

4. Values of analyzed parameters at baseline between intervention group and control group will be compared using Student’s t-tests for continuous variables or Chi-square tests for categorical variables according to the analysis plan.

5. Mann-Whitney U tests will be used where continuous data are not normally distributed. The primary analysis will employ analysis of covariance (ANCOVA) with baseline values of the analyzed endpoints used as covariates when appropriate. The mean level of each risk factor will also be compared between groups in terms of relative risks, 95% CIs and two-sided p values. We will conduct a pre-specified 2nd analysis with adjustment for patient characteristics as well as subgroup analyses based on age, sex, education, smoking status and tertiles level of endpoints.

6. All sample size calculations in both studies are for 80% power and 0.05 (one-sided) level of significance, allowing for 20% dropout rate during follow up.

7. In the CHAT study, we estimate a mean SBP level of 132mm Hg (SD, 18mm Hg) in the study population according to the report of previous studies, and assume an absolute reduction in SBP of 5 mm Hg at 6 months from baseline. A total sample size of 800 patients would be adequate to detect this difference in SBP between two groups even when considering the potential compliance to the intervention. In the CHAT-DM study, we assume a mean HbA1C level of 7.2% (SD, 1.6%) based on data from studies involving similar populations and supposed a 0.5% absolute decrease in HbA1C across treatment group. A
total sample size of 500 patients would be adequate to detect this difference in HbA1C between two groups even when considering the potential compliance to the intervention. The trial results will be reported in accordance with the SPIRIT checklists.

ETHICS AND DISSEMINATION

The findings of the study will be disseminated by standard scientific forums, including peer-review publications and presentations at conferences. The central ethics committee at the NCCD approved the CHAT and CHAT-DM studies. All collaborating hospitals accepted the central ethics approval except for 8, which obtained local approval by internal ethics committees. The Chinese government, which provides financial support, has no role in the design or conduct of the study, the collection, management, analysis, and interpretation of the data; or in the preparation or approval of articles resulting from the studies.

DISCUSSION

The CHAT and CHAT-DM studies aim to assess the efficacy of an innovative intervention for improving secondary prevention of CHD by using simple and cost-effective text-messaging technology among patients with known CHD, with or without DM, throughout China. To the best of our knowledge, these two trials are the first to investigate the efficacy of text messages to support management of CHD and DM among a large population in China, and may set
a model of such interventions that can be leveraged to improve risk factor management in resource-constrained settings.

The CHAT and CHAT-DM studies have several strengths. While prior studies evaluated the effectiveness of mobile phone text messaging to improve single individual health behaviors, very few trials have addressed the role of text messages in managing multiple risk factors in patients with CHD or DM, which is a reality for many patients. Patients with CHD and DM often have multiple risk factors, yet the care for these conditions is often fragmented. Targeting multiple risk factors concurrently instead of managing a single risk factor may be more efficient and impactful on disease management as this strategy is more patient-centered than disease-centered, and have a greater likelihood of improving risk factor control and cardiovascular outcomes. Additionally, there is currently little evidence about the effectiveness of such interventions for high-risk patients with coronary heart disease and diabetes.

The CHAT and CHAT-DM studies are further distinguished by their large sample sizes and culturally appropriate, theory-driven text messages. Most text message intervention studies that have focused on health behavior or diabetes management have had sample sizes ranging from 18-357 participants. CHAT has a sample size of around 790 while the sample size of CHAT-DM is 480. It is noteworthy that CHAT is the first study using theory-based text messaging as a method of delivery for CHD patients' behavior change in China. Data from other text messaging intervention studies suggest that text messaging programs achieved better results when message content is theory-based, however, few text messaging studies specified a theoretical rationale. Further, text messages were tailored to a specific
Chinese patient population. Studies have found that the majority of Chinese adults prefer learning by following directive rules and guidelines, and practical counseling instructions were provided through text messages to help them better modify health behaviors. Apart from this, the text message language was designed to be plain and easy to memorize, consistent with Chinese cultural features such as aphorism, chengyu and catchy rhyme schemes, making it more acceptable to patients.

The two studies have several additional strengths. In contrast to most prior single center text-messaging trials, these two studies are conducted at 37 participating sites spread across a large and geographically diverse country. These results may be more generalizable. Moreover, our research team devoted significant attention to quality data collection, including rigorous on-site monitoring of questionnaire answers, samples collection, and data management. Furthermore, an evaluation of the acceptability and feasibility of our text message-based intervention will provide further important evidence to inform future studies, particularly with regards to optimizing text content, text frequency, and the overall user experience.

Our study also has some potential limitations. First, medication adherence and physical activity are measured by self-report, which carries the possibility of recall bias and social desirability bias. However, we believe that any such bias would be balanced across the treatment and control groups, and MMAS-8 and IPAQ have been validated and are widely used in measuring these metrics. Second, the text messages, though semi-personalized with participant’s preferred name and depending on their smoking status, were not tailored specifically to every individual, which may reduce their efficacy. These
questions might be addressed in future studies using more individualized messages.

The CHAT and CHAT-DM studies have important public health implications. As low cost, non-pharmacological interventions, the CHAT and CHAT-DM studies may serve as important models for patient-centered, evidence-based public health interventions. LMICs, including China, face challenges with huge burdens of CVD and DM, limited health resources, and geographically and culturally diverse patient populations, making them the ideal places to conduct such studies. Still, high levels of mobile phone ownership across countries and income levels signal a promising new avenue for clinical research and that it may be possible to scale effective mobile health interventions for delivery to large populations in the coming years. Considering that text messages are low in cost and incur minimal, if any, risk, if this innovative and simple prevention were proven to be helpful, its benefits would be substantial in a country as large and populous as China.

In conclusion, the CHAT and CHAT-DM studies are multi-center, randomized controlled trials that are being conducted at 37 hospitals, and will thoroughly test the efficacy of text-messages to support secondary prevention for CHD and DM in China. The studies target high-risk patient populations with a culturally-sensitive, scalable and cost-effective text-message intervention. These two trials go through comprehensive data collection and rigorous data management, and have the potential to provide novel insights into disease management and be scaled-up to improve health in a significant proportion of patients in future.
Acknowledgments: We appreciate the multiple contributions made by study teams at the China Oxford Centre for International Health Research and the Yale-New Haven Hospital Center for Outcomes Research and Evaluation in the areas of study design and operations, particularly the contributions to the text message bank by Xuekun Wu, Si Xuan and Xiuling Wang, and data collection and analysis by Ying Sun, Chaoqun Wu, Xueke Bai, Jiamin Liu and Wuhanbilige Hundei. We appreciate the valuable advice from Clara Chow and her team in Sydney, Weigang Zhao, Geng Liu, Yuanlin Guo, Zhuo Xu and Zengwu Wang. We are also grateful for the support provided by the Chinese government.


Funding: This project was supported by the Research Special Fund for Public Welfare Industry of Health (201502009) from the National Health and Family Planning Commission of China, the National Key Technology R&D Program (2015BAI12B01, 2015BAI12B02) from the Ministry of Science and Technology of China and the 111 Project (B16005). Dr Spatz is supported by grant K12HS023000 from the Agency for Healthcare Research and Quality Patient-Centered Outcomes Research Institute (PCORI) Mentored Career Development Program. The sponsors had no role in the preparation or approval of the manuscript.
Competing interests: Dr. Krumholz is a recipient of research agreements from Medtronic and from Johnson & Johnson (Janssen), through Yale University, to develop methods of clinical trial data sharing. He is also the recipient of a grant from the Food and Drug Administration and Medtronic to develop methods for post-market surveillance of medical devices; and is the founder of Hugo, a personal health information platform. The other authors have no potential conflicts to disclose.

Ethical approval: The central ethics committee at the China National Center for Cardiovascular Disease (NCCD) approved the CHAT and CHAT-DM studies. All collaborating hospitals accepted the central ethics approval except for 8, which obtained local approval by internal ethics committees.

REFERENCES


29. Hall CS, Fottrell E, Wilkinson S, etc. Assessing the impact of mHealth interventions in low- and middle-income countries--what has been shown to work? *Glob Health Action*. 2014;7:25606.


41. Morisky DE, Green LW and Levine DM. Concurrent and predictive validity


1. 2015;36:393-415.

2. 54. Littrell R. Teaching students from Confucian cultures. 2005.
Figure Legends

Figure 1. Geographic distribution of sites in CHAT and CHAT-DM studies

Figure 2. Text Development Process
Table 1. Behavior change techniques used in message development and example messages

<table>
<thead>
<tr>
<th>Behavior change technique</th>
<th>Content/explanation</th>
<th>Example text message in English</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provide information about behavior-health link</td>
<td>General information about behavioral risk</td>
<td>The way you cook can impact your health as well. Steaming, boiling and sautéing are better ways to cook than deep-frying and pan-frying. Cooking in less oil is a healthy alternative.</td>
</tr>
<tr>
<td>Prompt barrier identification</td>
<td>Identify barriers to perform the behavior and plan ways of overcoming them</td>
<td>Taking diabetes medications and injecting insulin regularly can help control your blood sugar. Forgetting to take your medication? Try to set a repeating alarm on your cell phone to remind you to take your medication or insulin injection.</td>
</tr>
<tr>
<td>Set graded tasks</td>
<td>Set easy tasks, and increase difficulty until target behavior is reached</td>
<td>Have you been finding it hard to quit smoking? In the beginning things are always hard. You can use a schedule to gradually reduce the number of cigarettes you smoke. For example, you...</td>
</tr>
<tr>
<td>Provide instruction</td>
<td>Tell the person how to perform a behavior and/or preparatory behaviors</td>
<td>If you experience symptoms of angina (severe chest pain), place one nitroglycerin tablet under your tongue. Sit, stay calm and rest if you ever forget medications while going out. If angina symptoms are not relieved within 10 minutes, seek medical attention immediately.</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Prompt self-monitoring</td>
<td>The person is asked to keep a record of specified behavior(s)</td>
<td>A cold or diarrhea will make your blood sugar levels rise, so monitor your glucose more frequently when you are sick. If you are using insulin, test your blood glucose 6-8 times a day, keep a blood glucose log and share it with your health providers.</td>
</tr>
<tr>
<td>Prompt practice</td>
<td>Prompt the person to rehearse and repeat the behavior or preparatory behaviors</td>
<td>As an old Chinese saying goes, 'It takes more than one cold day for a river to freeze three feet deep; ice in the river takes a long time to melt.' Similarly, cerebrovascular disease requires</td>
</tr>
</tbody>
</table>
long-term prevention and treatment. Remember to take your medications as prescribed!

Plan social support or social change
Prompt consideration of how others could change their behavior to offer the person help or (instrumental) social support

Quitting smoking on your own can be difficult. Tell your friends and family when you are quitting so that they will stop giving you cigarettes. Support and encouragement from your loved one can be helpful as well.

Stress management
May involve a variety of specific techniques (e.g., progressive relaxation) that do not target the behavior but seek to reduce anxiety and stress

Relaxation is something we need to learn and practice. Listening to music, reading, or talking to friends and family can ease stress.

Motivational interviewing
Prompt the person to provide self-motivating statements and

Did you smoke less today than you did yesterday or days before?
If you did reduce the amount of cigarettes, it is something worth
evaluations of their own behaviors to minimize resistance to change. We are sure that you have put a lot of effort into quitting. Keep up the good work and you can make a difference!
### Table 2. Survey scores for various message categories in user test

<table>
<thead>
<tr>
<th>Category</th>
<th>Strongly agree or agree</th>
<th>Neutral</th>
<th>Strongly disagree or disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General health messages</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=142)</td>
<td>130 (91.6%)</td>
<td>6 (4.2%)</td>
<td>6 (4.2%)</td>
</tr>
<tr>
<td>Information was useful (n=142)</td>
<td>129 (90.9%)</td>
<td>9 (6.3%)</td>
<td>4 (2.8%)</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=181)</td>
<td>168 (92.8%)</td>
<td>7 (3.9%)</td>
<td>6 (3.3%)</td>
</tr>
<tr>
<td>Information was useful (n=181)</td>
<td>169 (93.4%)</td>
<td>6 (3.3%)</td>
<td>6 (3.3%)</td>
</tr>
<tr>
<td><strong>Medication Adherence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=149)</td>
<td>134 (89.9%)</td>
<td>10 (6.7%)</td>
<td>5 (3.4%)</td>
</tr>
<tr>
<td>Information was useful (n=149)</td>
<td>137 (92.0%)</td>
<td>10 (6.7%)</td>
<td>2 (1.3%)</td>
</tr>
<tr>
<td><strong>Physical Activity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Information easy to understand (n=116)</td>
<td>109 (93.9%)</td>
<td>6 (5.2%)</td>
<td>1 (0.9%)</td>
</tr>
<tr>
<td>Information was useful (n=116)</td>
<td>111 (95.7%)</td>
<td>4 (3.4%)</td>
<td>1 (0.9%)</td>
</tr>
</tbody>
</table>
(n=116)

**Smoking cessation**

Information easy to understand (n=42)

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>1 (2.4%)</td>
</tr>
</tbody>
</table>

Information was useful (n=42)

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>41 (97.6%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

(continued on next page)
Table 3. Example Text Messages for the CHAT and CHAT-DM Studies

<table>
<thead>
<tr>
<th>CHAT TEXT [6 texts/wk]</th>
<th>CHAT-DM TEXT [6 texts/wk]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Education (CVD) [2x/wk]</strong></td>
<td><strong>General Education (DM) [1x/wk]</strong></td>
</tr>
<tr>
<td>The most common risk factors for coronary artery disease are smoking, obesity, high blood pressure, high cholesterol and diabetes. However, most of them can be controlled in an appropriate way.</td>
<td>Diabetes is not terrible and there are many things you can do to prevent problems from diabetes, such as monitoring blood glucose, watching your diet, keeping fit, and taking pills regularly.</td>
</tr>
<tr>
<td><strong>Blood Pressure Control [2x/wk]</strong></td>
<td><strong>Blood Pressure Control [1x/wk]</strong></td>
</tr>
<tr>
<td>Most people do not experience any symptoms of high blood pressure. Do not stop taking blood pressure medication unless directed by your doctor. It is important for patients with hypertension to take medication diligently and to monitor their blood pressure on a regular basis.</td>
<td>Home Blood Pressure Monitoring is highly recommended! You can get an accurate picture of your heart health and understand daily changes in blood pressure, which is helpful for doctors to adjust medications for you.</td>
</tr>
<tr>
<td><strong>Medication Adherence [1x/wk]</strong></td>
<td><strong>Medication Adherence [1x/wk]</strong></td>
</tr>
<tr>
<td>Do you have a problem remembering to take your blood pressure medications? If so, try to tell your family about your medicine schedule so they can remind you.</td>
<td>Talk to doctors about your concerns and any uncomfortable symptoms after taking pills. Let your doctor help you to find the right medication for you.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>
| **Physical Activity [1x/wk]**  
You can still choose low-intensity exercise even after heart attack, such as walking and Tai Chi, at a slower pace and stick to your exercise plan. Always consult your physician before beginning any exercise program. | **Physical Activity [1x/wk]**  
Try brisk walking – a convenient, safe and cost-effective way of exercising! It’s good for your heart and will help control blood glucose. |
| **Smoking Cessation [1x/wk]**  
Do you worry about your family having health problems because of your smoking? Quitting is an important choice you can make to benefit your family’s health, too. Secondhand smoke can cause respiratory disease, lung cancer, and heart disease. | **Diabetes Management [1x/wk]**  
See a doctor before you travel. Always carry your diabetes medications and insulin, glucose meter, and strips, so that you can better monitor your glucose. Carry some hard candy and crackers to avoid low sugar. |
<table>
<thead>
<tr>
<th>Life style intervention [1x/wk]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals with diabetes should consume a balanced diet, and eat smaller but more frequent meals. Consider splitting your meal and save it for a snack later. Some healthy snack choices include tomatoes, cucumbers, and sugar-free biscuits.</td>
</tr>
</tbody>
</table>

* In CHAT, non-smokers receive two General Education messages per week, while smokers only receive one per week. 

† In CHAT, only smokers receive smoking cessation messages.
**Table 4. Baseline and follow-up data collection**

<table>
<thead>
<tr>
<th>Information</th>
<th>Baseline</th>
<th>6 month</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic and contact information</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Physical examination: BP, HR, waist</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>waist circumference, weight, height</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ambulatory blood pressure</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Outcome (death, myocardial infarction, angina, stroke, revascularization, etc.)</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Hospitalizations</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Current medications</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Medication adherence (Morisky)</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Physical activity (IPAQ)</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>CVD functional status (SAQ)</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Health status (EQ-5D)</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Risk factors control</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Urine cotinine/nicotine test</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>Blood and urine sample for core lab</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>and local test</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1. Geographic distribution of sites in CHAT and CHAT-DM studies

110x72mm (300 x 300 DPI)
Figure 2. Text Development Process

Phase 1
Initial Text Development
≈550 text messages drafted based on BCTs and AHA guidelines

Phase 2
Expert Review
Text messages shared with Chinese and English experts (students and patients)
Messages Refined based on:
Expert CVD/BCT Review (3x)
English/Chinese Review (3x)

Phase 3
User Testing and Pilot Study
Automated Software System Developed
Participants receive text messages for 1 month and give feedback
Messages/Software Refined
based on participant and developer feedback

CHAT Final Text Bank
280 text messages finalized and ready for inclusion in the CHAT intervention

CHAT-DM Final Text Bank
270 text messages finalized and ready for inclusion in the CHAT-DM intervention
Supplementary Materials

Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

TABLE OF CONTENTS

Page 2-3: CHAT and CHAT-DM studies site investigators by hospital
CHAT and CHAT-DM studies site investigators by hospital

1. China-Japan Union Hospital of Jilin University, Ping Yang, Zhaohui Feng, Mei Ding, Bing Li;
2. Dongfeng County Hospital, Wei Liu, Xiaoxin Li, Yanbin Zhang, Wen Cui, Sen Shi;
3. First Hospital of Shanxi Medical University, Qinghua Han, Liqin Duan, Chunrong Jin;
4. General Hospital of China FAW Group Corporation, Hongtao Pan, Lei Sun, Peng Chen;
5. Inner Mongolia Baogang Hospital, Yongdong Li, Liqing Jia, Xingxing Ren;
6. Jiangxi Provincial People's Hospital, Lang Hong, Ji Hong, Linfeng Li, Lihua Yuan, Yun Li;
7. Laixi People's Hospital, Xu Jiang, Hui Liu, Guohao Xu, Yanrong Song;
8. Laoting County Hospital, Keyong Shang, Changjiang Liu, Kuituan Xi, Ying Yu;
9. Lujiang County People's Hospital, Kelian Xu, Cunqi Wang, Yongan Qian;
10. Nanyang Central Hospital, Shouzhong Yang, Yudong Li, Jianbu Gao, Songyu Zhang;
11. Port Hospital of Hebei Port Group Company, Ltd, Xia Wu, Penghui Yang, Xueqing Wang;
12. Qingdao Fuwai Hospital, Xianyan Jiang, Bin Zhang, Yumei Dong, Cheng Zheng, Wenchuan Hu;
13. Qinghai Cardiovascular and Cerebrovascular Hospital, Huiping Bian, Bo Chen, Xiaojuan Han, Na Han;
14. Qinzhou Second People's Hospital, Liyuan Chen, Qiuxia Liu, Lin Chen;
15. Quwo County People's Hospital, Xiwu Wang, Zhenlin Wu, Qiang Wang, Zhaohui Shangguan;
16. Shanxi Cardiovascular Hospital, Bin Yang, Yingting Yang;
17. Shenyang the Fourth Hospital of People, Yinjun Li, Wei Jiang;
18. Shuangcheng People's Hospital, Cheng Zhang, Aiguo Sun, Xuemei Wang;
19. Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Feng Liu, Qiaoxia Zhou,
   Bingbing Zhu, Jie Guo;
20. The Affiliated Hospital of Qingdao University, Changyong Zhou, Yini Wang, Tao Yu, Zhe Su;
21. The First Affiliated Hospital of Fujian Medical University, Jinxiu Lin, Dajun Chai, Qinghui Guo;
22. The Affiliated Hospital of Xuzhou Medical University, Dongye Li, Yuanyuan Luo, Junhong Chen, Wei
   Qian, Qian Yu, Lulu Sun;
23. The First Hospital of Jilin University, Yang Zheng, Zhaoxi Liu, Lin Zou;
24. The Fourth Affiliated Hospital of China Medical University, Yuanzhe Jin, Xiaohong Zhang, Weina Hu;
25. The people's hospital of Dongxihu district of Wuhan, Yongbo Lin, Ling Zhou, Hanliang Dan;
26. The People's Hospital of Liaoning Province, Zhanquan Li, Ying Liu, Dan Li;
27. The Second Affiliated Hospital of Xuzhou Medical College, Weiheng Wu, Li Li, Sai Zhang;
28. The Second Affiliated Hospital of Zhengzhou University, Xianen Fa, Lihua Zhang, Liqiang Sun, Youxu Jiang;
29. Tianjin Medical University General Hospital, Yuemin Sun, Bo Bian;
30. TEDA International Cardiovascular Hospital, Zhigang Liu, Zhipeng Guo, Cun Zhang;
31. Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Jiangang Jiang, Xiaoqing Shen, Ting Yu;
32. Wuhan Asia Heart Hospital, Xi Su, Songzhi Zhao, Wei Wu, Yujing Fan;
33. Wulate County People’s Hospital, Jinlan Xu, Lei Xia, Yunmei Wang;
34. Xiangtan Central Hospital, He Huang, Jianping Zeng, Mingxing Wu, Yi Zhou;
35. Xinmin People’s Hospital, Bo Jiang, Liwei Qi, Tongying Li;
36. Xuzhou First People’s Hospital, Hongju Zhang, Chen Bian, Wei Li;
37. Zhengzhou Central Hospital, Lin Zhang, Yumei Guo;
## SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administrative information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>N/A</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>N/A</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>23</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>1-2</td>
</tr>
<tr>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>23-24</td>
</tr>
</tbody>
</table>
Introduction

Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention ______5-6_____

6b Explanation for choice of comparators ______5-6_____

Objectives 7 Specific objectives or hypotheses ______7_____

Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) ______8-9_____

Methods: Participants, interventions, and outcomes

Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained ______7_____

Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) ______8_____

Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered ______8-12_____

11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) ______9_____

11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) ______14_____

11d Relevant concomitant care and interventions that are permitted or prohibited during the trial ______9_____

Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended ______16-17_____

Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) ______7_____

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open: first published as 10.1136/bmjopen-2017-018302 on 21 December 2017. Downloaded from.
| Sample size | 14 | Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations |
| Recruitment | 15 | Strategies for achieving adequate participant enrolment to reach target sample size |

**Methods: Assignment of interventions (for controlled trials)**

**Allocation:**

| Sequence generation | 16a | Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions |
| Allocation concealment mechanism | 16b | Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned |
| Implementation | 16c | Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions |

**Blinding (masking):**

| Blinding (masking) | 17a | Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how |
| 17b | If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s allocated intervention during the trial |

**Methods: Data collection, management, and analysis**

<p>| Data collection methods | 18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol |
| 18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols |</p>
<table>
<thead>
<tr>
<th>Topic</th>
<th>Section</th>
<th>Details</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data management</td>
<td>19</td>
<td>Plans for data entry, coding, security, and storage, including any related processes to promote data quality (e.g., double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol.</td>
<td>15-16</td>
</tr>
<tr>
<td>Statistical methods</td>
<td>20a</td>
<td>Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol.</td>
<td>18-19</td>
</tr>
<tr>
<td></td>
<td>20b</td>
<td>Methods for any additional analyses (e.g., subgroup and adjusted analyses)</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>20c</td>
<td>Definition of analysis population relating to protocol non-adherence (e.g., as randomised analysis), and any statistical methods to handle missing data (e.g., multiple imputation)</td>
<td>N/A</td>
</tr>
<tr>
<td>Methods: Monitoring</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data monitoring</td>
<td>21a</td>
<td>Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial.</td>
<td>N/A</td>
</tr>
<tr>
<td>Harms</td>
<td>22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td>15</td>
</tr>
<tr>
<td>Auditing</td>
<td>23</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor.</td>
<td>N/A</td>
</tr>
<tr>
<td>Ethics and dissemination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research ethics approval</td>
<td>24</td>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval.</td>
<td>24</td>
</tr>
<tr>
<td>Protocol amendments</td>
<td>25</td>
<td>Plans for communicating important protocol modifications (e.g., changes to eligibility criteria, outcomes, analyses) to relevant parties (e.g., investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>N/A</td>
</tr>
<tr>
<td>Item</td>
<td>Description</td>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>26a</td>
<td>Consent or assent</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how <strong><strong><strong>7</strong></strong></strong> (see Item 32)</td>
<td></td>
</tr>
<tr>
<td>26b</td>
<td>Additional consent provisions</td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable ____ N/A ____</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Confidentiality</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial ___ 15-16 ____</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Declaration of interests</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site ___ 24 ____</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Access to data</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators ___ 15-16 ____</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Ancillary and post-trial care</td>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation ____ N/A ____</td>
<td></td>
</tr>
<tr>
<td>31a</td>
<td>Dissemination policy</td>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions ___ 19 ____</td>
<td></td>
</tr>
<tr>
<td>31b</td>
<td>Authorship eligibility guidelines</td>
<td>Authorship eligibility guidelines and any intended use of professional writers ___ 23 ____</td>
<td></td>
</tr>
<tr>
<td>31c</td>
<td>Plans for granting public access</td>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code ____ N/A ____</td>
<td></td>
</tr>
</tbody>
</table>

**Appendices**

<table>
<thead>
<tr>
<th>Item</th>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>Informed consent materials</td>
<td>Model consent form and other related documentation given to participants and authorised surrogates ____ N/A ____</td>
</tr>
<tr>
<td>33</td>
<td>Biological specimens</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable ____ N/A ____</td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.*
Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

<table>
<thead>
<tr>
<th>Journal:</th>
<th>BMJ Open</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bmjopen-2017-018302.R2</td>
</tr>
<tr>
<td>Article Type</td>
<td>Protocol</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>24-Oct-2017</td>
</tr>
</tbody>
</table>
| Complete List of Authors: | Huo, Xiqian; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Spatz, Erica; Yale University  
Ding, Qinglan; Yale University  
Horak, Paul ; Yale University  
Zheng, Xin; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Masters, Claire ; Yale University  
Zhang, Haibo; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research  
Irwin, Melinda; Yale School of Public Health  
Yan, Xiaofang; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Guan, Wenchi; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research  
Li, Jing; Cardiovascular Institute & Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China Oxford Centre for International Health Research  
Li, Xi; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease  
Spertus, John; Mid America Heart Institute of Saint Luke's Hospital  
Masoudi, Frederick; Division of Cardiology, University of Colorado Anschutz Medical Campus  
Krumholz, Harlan; Yale School of Public Health  
Jiang, Lixin; Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease |

**Primary Subject Heading:** Research methods

**Secondary Subject Heading:** Research methods, Medical management

**Keywords:** Coronary heart disease < CARDIOLOGY, diabetes, text messaging, behavioral intervention, secondary prevention
Figure 1. Geographic distribution of sites in CHAT and CHAT-DM studies

110x72mm (300 x 300 DPI)
Figure 2. Text Development Process

Phase 1
Initial Text Development
~550 text messages drafted based on BCTs and AHA guidelines

Phase 2
Expert Review
Text messages shared with Chinese and English experts (students and patients)

Messages Refined based on:
Expert CVD/BCT Review (3x)
English/Chinese Review (3x)

Phase 3
User Testing and Pilot Study
Automated Software System Developed
Participants receive text messages for 1 month and give feedback

Messages/Software Refined based on participant and developer feedback

CHAT Final Text Bank
280 text messages finalized and ready for inclusion in the CHAT intervention

CHAT-DM Final Text Bank
270 text messages finalized and ready for inclusion in the CHAT-DM intervention
Supplementary Materials

Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomized controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes

TABLE OF CONTENTS

Page 2-3: CHAT and CHAT-DM studies site investigators by hospital
CHAT and CHAT-DM studies site investigators by hospital

1. China-Japan Union Hospital of Jilin University, Ping Yang, Zhaohui Feng, Mei Ding, Bing Li;
2. Dongfeng County Hospital, Wei Liu, Xiaoxin Li, Yanbin Zhang, Wen Cui, Sen Shi;
3. First Hospital of Shanxi Medical University, Qinghua Han, Liqin Duan, Chunrong Jin;
4. General Hospital of China FAW Group Corporation, Hongtao Pan, Lei Sun, Peng Chen;
5. Inner Mongolia Baogang Hospital, Yongdong Li, Liqing Jia, Xingxing Ren;
6. Jiangxi Provincial People’s Hospital, Lang Hong, Ji Hong, Linfeng Li, Lihua Yuan, Yun Li;
7. Laixi People’s Hospital, Xu Jiang, Hui Liu, Guohao Xu, Yanrong Song;
8. Laoting County Hospital, Keyong Shang, Changjiang Liu, Kuituan Xi, Ying Yu;
9. Luijiang County People’s Hospital, Kelian Xu, Cunqi Wang, Yongan Qian;
10. Nanyang Central Hospital, Shouzhong Yang, Yudong Li, Jianbu Gao, Songyu Zhang;
11. Port Hospital of Hebei Port Group Company, Ltd, Xia Wu, Penghui Yang, Xueqing Wang;
12. Qingdao Fuwai Hospital, Xianyan Jiang, Bin Zhang, Yumei Dong, Cheng Zheng, Wenchuan Hu;
13. Qinghai Cardiovascular and Cerebrovascular Hospital, Huiping Bian, Bo Chen, Xiaojuan Han, Na Han;
14. Qinzhou Second People’s Hospital, Liyuan Chen, Qiuxia Liu, Lin Chen;
15. Quwo County People’s Hospital, Xiwu Wang, Zhenlin Wu, Qiang Wang, Zhaohui Shangguan;
16. Shanxi Cardiovascular Hospital, Bin Yang, Yingting Yang;
17. Shenyang the Fourth Hospital of People, Yinjun Li, Wei Jiang;
18. Shuangcheng People's Hospital, Cheng Zhang, Aiguo Sun, Xuemei Wang;
19. Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Feng Liu, Qiaoxia Zhou, Bingbing Zhu, Jie Guo;
20. The Affiliated Hospital of Qingdao University, Changyong Zhou, Yini Wang, Tao Yu, Zhe Su;
21. The First Affiliated Hospital of Fujian Medical University, Jinxiu Lin, Dajun Chai, Qinghui Guo;
22. The Affiliated Hospital of Xuzhou Medical University, Dongye Li, Yuanyuan Luo, Junhong Chen, Wei Qian, Qian Yu, Lulu Sun;
23. The First Hospital of Jilin University, Yang Zheng, Zhaoxi Liu, Lin Zou;
24. The Fourth Affiliated Hospital of China Medical University, Yuanzhe Jin, Xiaohong Zhang, Weina Hu;
25. The people’s hospital of Dongxihu district of Wuhan, Yongbo Lin, Ling Zhou, Hanliang Dan;
26. The People’s Hospital of Liaoning Province, Zhanquan Li, Ying Liu, Dan Li;
27. The Second Affiliated Hospital of Xuzhou Medical College, Weiheg Wu, Li Li, Sai Zhang;
28. The Second Affiliated Hospital of Zhengzhou University, Xianen Fa, Lihua Zhang, Liqiang Sun, Youxu Jiang;
29. Tianjin Medical University General Hospital, Yuemin Sun, Bo Bian;
30. TEDA International Cardiovascular Hospital, Zhigang Liu, Zhipeng Guo, Cun Zhang;
31. Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Jiangang Jiang, Xiaoqing Shen, Ting Yu;
32. Wuhan Asia Heart Hospital, Xi Su, Songzhi Zhao, Wei Wu, Yujing Fan;
33. Wulate County People’s Hospital, Jinlan Xu, Lei Xia, Yunmei Wang;
34. Xiangtan Central Hospital, He Huang, Jianping Zeng, Mingxing Wu, Yi Zhou;
35. Xinmin People’s Hospital, Bo Jiang, Liwei Qi, Tongying Li;
36. Xuzhou First People’s Hospital, Hongju Zhang, Chen Bian, Wei Li;
37. Zhengzhou Central Hospital, Lin Zhang, Yumei Guo;
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Administrative information</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>N/A</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>N/A</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>23</td>
</tr>
<tr>
<td>Roles and</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>1-2</td>
</tr>
<tr>
<td>responsibilities</td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>23-24</td>
</tr>
</tbody>
</table>
Introduction

Background and rationale

6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention 5-6

6b Explanation for choice of comparators 5-6

Objectives

7 Specific objectives or hypotheses 7

Trial design

8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 8-9

Methods: Participants, interventions, and outcomes

Study setting

9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained 7

Eligibility criteria

10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) 8

Interventions

11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered 8-12

11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) 9

11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) 14

11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 9

Outcomes

12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended 16-17

Participant timeline

13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 7
### Methods: Assignment of interventions (for controlled trials)

<table>
<thead>
<tr>
<th>Allocation</th>
<th>16a</th>
<th>Method of generating the allocation sequence (e.g., computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (e.g., blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions</th>
<th>8-9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment mechanism</td>
<td>16b</td>
<td>Mechanism of implementing the allocation sequence (e.g., central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned</td>
<td>9</td>
</tr>
<tr>
<td>Implementation</td>
<td>16c</td>
<td>Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions</td>
<td>8-9</td>
</tr>
<tr>
<td>Blinding (masking)</td>
<td>17a</td>
<td>Who will be blinded after assignment to interventions (e.g., trial participants, care providers, outcome assessors, data analysts), and how</td>
<td>9</td>
</tr>
<tr>
<td>17b</td>
<td>If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

### Methods: Data collection, management, and analysis

<p>| Data collection methods | 18a | Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (e.g., duplicate measurements, training of assessors) and a description of study instruments (e.g., questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol | 14-15 |
| 18b | Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols | N/A |</p>
<table>
<thead>
<tr>
<th>Section</th>
<th>Item</th>
<th>Description</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data management</td>
<td>19</td>
<td>Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol.</td>
<td>15-16</td>
</tr>
<tr>
<td>Statistical methods</td>
<td>20a</td>
<td>Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol.</td>
<td>18-19</td>
</tr>
<tr>
<td></td>
<td>20b</td>
<td>Methods for any additional analyses (eg, subgroup and adjusted analyses)</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>20c</td>
<td>Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)</td>
<td>N/A</td>
</tr>
<tr>
<td>Methods: Monitoring</td>
<td>21a</td>
<td>Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
<td>N/A</td>
</tr>
<tr>
<td>Harms</td>
<td>22</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td>15</td>
</tr>
<tr>
<td>Auditing</td>
<td>23</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
<td>N/A</td>
</tr>
<tr>
<td>Ethics and dissemination</td>
<td>24</td>
<td>Plans for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>25</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>N/A</td>
</tr>
<tr>
<td>Item</td>
<td>Description</td>
<td>Pages</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>26a</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>26b</td>
<td>Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>15-16</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>15-16</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>31a</td>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>31b</td>
<td>Authorship eligibility guidelines and any intended use of professional writers</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>31c</td>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

**Appendices**

- 32: Model consent form and other related documentation given to participants and authorised surrogates
- 33: Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license.*
Correction: Design and rationale of the Cardiovascular Health and Text Messaging (CHAT) Study and the CHAT-Diabetes Mellitus (CHAT-DM) Study: two randomised controlled trials of text messaging to improve secondary prevention for coronary heart disease and diabetes


The equal contributors statement should read: “XH and ESS are Joint first authors. HMK and LJ are Joint senior authors.”

The ‘Contributions’ section at the end of the paper should read: “ESS, XZ, MLI, JL, XL, LJ, JAS, FAM, HMK, LJ: study concept and design; All authors except XY, HZ are involved in designing the study text messages; XH, XZ, HZ, XY, XL are involved in the implementation of the project; XH, ESS, QD, PH, CM drafting the initial manuscript. All authors provided critical revision of the paper, read and approved the final manuscript.”

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.